

Real-World Evidence Collaborative White Paper Citations Tracker

The Duke-Margolis Institute for Health Policy's Real-World Evidence Collaborative is proud to have its white papers cited in a diverse number of publications. The following running list of citations is current as of February 2025.

Table of Contents

A Framework for Regulatory Use of Real-World Evidence	Page 2
Characterizing RWD Quality and Relevancy for Regulatory Purposes	Page 17
Determining Real-World Data's Fitness for Use and the Role of Reliability	Page 24
Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility	Page 32
Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness	Page 35
A Roadmap for Developing Study Endpoints in Real-World Settings	Page 39
Point-of-Care Clinical Trials: Integrating Research and Care Delivery	Page 41
Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem	Page 43
Improving Patient Subgroup Representation with Real-World Data	Page 44
Lessons from Learning Health Care Systems and Recommendations for Successful Implementation	Page 45
Real-World Evidence to Support Causal Inference: Methodological Considerations for Non-Interventional Studies	Page 46

A Framework for Regulatory Use of Real-World Evidence

“The First White Paper” | Published September 2017

1. Akehurst, Ron, Linda A. Murphy, Oriol Solà-Morales, David Cunningham, Jorge Mestre-Ferrandiz, and Gérard de Pouvourville. “Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties and a Pragmatic Way Forward.” *Value in Health*, January 24, 2023. <https://doi.org/10.1016/j.jval.2023.01.010>.
2. Alipour-Haris, Golnoosh, Xinyue Liu, Virginia Acha, Almut G. Winterstein, and Mehmet Burcu. “Real-World Evidence to Support Regulatory Submissions: A Landscape Review and Assessment of Use Cases.” *Clinical and Translational Science* 17, no. 8 (2024): e13903. <https://doi.org/10.1111/cts.13903>.
3. Anderson, Peter, Victoria Higgins, Jonathan de Courcy, Katerina Doslikova, Victoria A. Davis, Maria Karavali, and James Piercy. “Real-World Evidence Generation from Patients, Their Caregivers and Physicians Supporting Clinical, Regulatory and Guideline Decisions: An Update on Disease Specific Programmes.” *Current Medical Research and Opinion* 39, no. 12 (December 2, 2023): 1707–15. <https://doi.org/10.1080/03007995.2023.2279679>.
4. Antonijevic, Zoran, and Robert A. Beckman. *Platform Trial Designs in Drug Development: Umbrella Trials and Basket Trials*. CRC Press, 2018.
5. Anzueto, Antonio, and Alan Kaplan. “Dual Bronchodilators in Chronic Obstructive Pulmonary Disease: Evidence from Randomized Controlled Trials and Real-World Studies.” *Respiratory Medicine: X* 2 (November 1, 2020): 100016. <https://doi.org/10.1016/j.yrmex.2020.100016>.
6. Armağan, Berkan, Levent Kılıç, Fatoş Önen, and Sedat Kiraz. “Real-Life Parameters in Rheumatology.” *Ulusal Romatoloji Dergisi* 12, no. Special Issue (December 2020): 73–80. <https://doi.org/10.4274/raed.galenos.2020.S110>.
7. Arondekar, Bhakti, Mei Sheng Duh, Rachel H. Bhak, Maral DerSarkissian, Lynn Huynh, Kelsey Wang, John Wojciehowski, et al. “Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020.” *Clinical Cancer Research* 28, no. 1 (January 1, 2022): 27–35. <https://doi.org/10.1158/1078-0432.CCR-21-2639>.
8. A.S. Kolbin and D. Yu. Belousov. “Chinese experience on using RWE to support drug research, development and evaluation.” *Real-World Data & Evidence* 1, no. 2 (March 2022): 17–27.

9. Austin, Jodie A., Elton H. Lobo, Mahnaz Samadbeik, Teyl Engstrom, Reji Philip, Jason D. Pole, and Clair M. Sullivan. "Decades in the Making: The Evolution of Digital Health Research Infrastructure Through Synthetic Data, Common Data Models, and Federated Learning." *Journal of Medical Internet Research* 26, no. 1 (December 20, 2024): e58637. <https://doi.org/10.2196/58637>.
10. Barberio, Julie, Rohini K Hernandez, Ashley I Naimi, Rachel E Patzer, Christopher Kim, and Timothy L Lash. "Characterizing Fit-for-Purpose Real-World Data: An Assessment of a Mother–Infant Linkage in the Japan Medical Data Center Claims Database." *Clinical Epidemiology* 16 (December 31, 2024): 31–43. <https://doi.org/10.2147/CLEP.S429246>.
11. Baumfeld Andre, Elodie, Robert Reynolds, Patrick Caubel, Laurent Azoulay, and Nancy A. Dreyer. "Trial Designs Using Real-World Data: The Changing Landscape of the Regulatory Approval Process." *Pharmacoepidemiology and Drug Safety* 29, no. 10 (2020): 1201–12. <https://doi.org/10.1002/pds.4932>.
12. Berkan Armagan, Levent Kilic, Fatos Onen, and Sedat Kiraz. "Real-life parameters in rheumatology." *Journal of Turkish Society for Rheumatology* 12 (2020): 73–80.
13. Bettina Schneider, Petra Maria Asprion, and Frank Grimberg. "Human-Centered Artificial Intelligence: A Multidimensional Approach towards Real World Evidence." In *Proceedings of the 21st International Conference on Enterprise Information Systems*, 381–90. Science and Technology Publications, 2019.
14. Brown, Jeremy P., Ian J. Douglas, Shahid Hanif, Robert M. A. Thwaites, and Andrew Bate. "Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact." *Value in Health* 24, no. 9 (September 1, 2021): 1241–44. <https://doi.org/10.1016/j.jval.2021.03.020>.
15. Bruxvoort, Katia, Lina S Sy, Yi Luo, and Hung Fu Tseng. "Real-World Evidence for Regulatory Decisions: Concomitant Administration of Zoster Vaccine Live and Pneumococcal Polysaccharide Vaccine." *American Journal of Epidemiology* 187, no. 9 (September 1, 2018): 1856–62. <https://doi.org/10.1093/aje/kwy076>.
16. Burcu, Mehmet, Nancy A. Dreyer, Jessica M. Franklin, Michael D. Blum, Cathy W. Critchlow, Eleanor M. Perfetto, and Wei Zhou. "Real-World Evidence to Support Regulatory Decision-Making for Medicines: Considerations for External Control Arms." *Pharmacoepidemiology and Drug Safety* 29, no. 10 (2020): 1228–35. <https://doi.org/10.1002/pds.4975>.
17. Caleigh Propes, Sarah Sheehan, and Rachele Hendricks-Sturup. "Point-of-Care Clinical

Trials: Integrating Research and Care Delivery." Duke-Margolis Center for Health Policy, May 11, 2022. <https://healthpolicy.duke.edu/publications/point-care-clinical-trials-integrating-research-and-care-delivery>.

18. Christian, Jennifer B., Emily S. Brouwer, Cynthia J. Girman, Dimitri Bennett, Kourtney J. Davis, and Nancy A. Dreyer. "Masking in Pragmatic Trials: Who, What, and When to Blind." *Therapeutic Innovation & Regulatory Science* 54, no. 2 (March 1, 2020): 431–36. <https://doi.org/10.1007/s43441-019-00073-7>.
19. Daigl, Monica, Seye Abogunrin, Felipe Castro, Sarah F McGough, Rachele Hendricks Sturup, Cornelis Boersma, and Keith R Abrams. "Advancing the Role of Real-World Evidence in Comparative Effectiveness Research." *Journal of Comparative Effectiveness Research* 0, no. 0 (September 2024): e240101. <https://doi.org/10.57264/cer-2024-0101>.
20. Dang, Lauren E., Susan Gruber, Hana Lee, Issa Dahabreh, Elizabeth A. Stuart, Brian D. Williamson, Richard Wyss, et al. "A Causal Roadmap for Generating High-Quality Real-World Evidence." arXiv, May 11, 2023. <https://doi.org/10.48550/arXiv.2305.06850>.
21. Daphne Guinn, Subha Madhavan, and Robert A. Beckman. "Harnessing Real-World Data to Inform Platform Trial Design." In *Platform Trial Designs in Drug Development*, First., 2018.
22. Daubner-Bendes, Rita, Sándor Kovács, Maciej Niewada, Mirjana Huic, Michael Drummond, Oriana Ciani, Carl Rudolf Blankart, et al. "Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges." *Frontiers in Public Health* 8 (2021). <https://www.frontiersin.org/articles/10.3389/fpubh.2020.612410>.
23. Dayer, Victoria W., Michael F. Drummond, Omar Dabbous, Mondher Toumi, Peter Neumann, Sean Tunis, Nelson Teich, et al. "Real-World Evidence for Coverage Determination of Treatments for Rare Diseases." *Orphanet Journal of Rare Diseases* 19, no. 1 (February 7, 2024): 47. <https://doi.org/10.1186/s13023-024-03041-z>.
24. De, Sugato, Leanne Larson, Kim Kelly, Beate Hanson, and Christina D. Mack. "Leveraging Real-World Evidence: A Paradigm Shift in Regulation." *Journal of Orthopaedic Trauma* 35 (March 2021): S13. <https://doi.org/10.1097/BOT.0000000000002039>.
25. Douglas Faries, Xiang Zhang, Zbigniew Kadziola, Uwe Siebert, Felicitas Kuehne, Robert L Obenchain, and Josep Maria Haro. "Introduction to Observational and Real World Evidence Research." In *Real World Health Care Data Analysis: Causal Methods and Implementation Using SAS*. SAS Institute, 2020.

26. Dreyer, Nancy A. "Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable." *Therapeutic Innovation & Regulatory Science* 52, no. 3 (May 1, 2018): 362–68. <https://doi.org/10.1177/2168479018763591>.
27. Dreyer, Nancy A, and Christina D Mack. "Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice." *Pragmatic and Observational Research* 14, no. null (December 31, 2023): 101–10. <https://doi.org/10.2147/POR.S396024>.
28. Dron, Louis, Shirin Golchi, Grace Hsu, and Kristian Thorlund. "Minimizing Control Group Allocation in Randomized Trials Using Dynamic Borrowing of External Control Data – An Application to Second Line Therapy for Non-Small Cell Lung Cancer." *Contemporary Clinical Trials Communications* 16 (December 1, 2019): 100446. <https://doi.org/10.1016/j.conctc.2019.100446>.
29. Enogela, Ene M., Taylor Buchanan, Christy S. Carter, Ronit Elk, Shena B. Gazaway, Burel R. Goodin, Elizabeth A. Jackson, et al. "Preserving Independence among Under-Resourced Older Adults in the Southeastern United States: Existing Barriers and Potential Strategies for Research." *International Journal for Equity in Health* 21, no. 1 (August 27, 2022): 119. <https://doi.org/10.1186/s12939-022-01721-5>.
30. Erin Hammers Forstag, Benjamin Kahn, Amanda Wagner Gee, and Carolyn Shore. "Examining the Impact of Real-World Evidence on Medical Product Development: Proceedings of a Workshop Series." The National Academies Press, 2019. <https://nap.nationalacademies.org/catalog/25352/examining-the-impact-of-real-world-evidence-on-medical-product-development>.
31. Faries, Douglas, Xiang Zhang, Zbigniew Kadziola, Uwe Siebert, Felicitas Kuehne, Robert L. Obenchain, and Josep Maria Haro. *Real World Health Care Data Analysis: Causal Methods and Implementation Using SAS*. SAS Institute, 2020.
32. Girman, Cynthia J., Mary E. Ritchey, Wei Zhou, and Nancy A. Dreyer. "Considerations in Characterizing Real-world Data Relevance and Quality for Regulatory Purposes: A Commentary." *Pharmacoepidemiology and Drug Safety* 28, no. 4 (April 2019): 439–42. <https://doi.org/10.1002/pds.4697>.
33. Gliklich, Richard E., and Michelle B. Leavy. "Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence." *Therapeutic Innovation & Regulatory Science* 54, no. 2 (March 1, 2020): 303–7. <https://doi.org/10.1007/s43441-019-00058-6>.

34. Grabner, Michael, Cliff Molife, Liya Wang, Katherine B. Winfree, Zhanglin Lin Cui, Gebra Cuyun Carter, and Lisa M. Hess. "Data Integration to Improve Real-World Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration." *JMIR Cancer* 7, no. 2 (April 12, 2021): e23161. <https://doi.org/10.2196/23161>.
35. Gregory Daniel, Christina Silcox, Jonathan Bryan, Mark McClellan, Morgan Romine, and Katherine Frank. "Characterizing RWD Quality and Relevancy for Regulatory Purposes." Duke-Margolis Center for Health Policy, October 1, 2018. <https://healthpolicy.duke.edu/publications/characterizing-rwd-quality-and-relevancy-regulatory-purposes-0>.
36. Guinn, Daphne, Erin E. Wilhelm, Grazyna Lieberman, and Sean Khozin. "Assessing Function of Electronic Health Records for Real-World Data Generation." *BMJ Evidence-Based Medicine* 24, no. 3 (June 1, 2019): 95–98. <https://doi.org/10.1136/bmjebm-2018-111111>.
37. Hallersten, Anna Margareta, Nicholas Michael Decker, and Yasha Huang. "Principles of Ideal Diagnostic Regulation and the IVDR." *Clinical Chemistry and Laboratory Medicine (CCLM)* 61, no. 4 (March 1, 2023): 599–607. <https://doi.org/10.1515/cclm-2022-1206>.
38. Hendricks-Sturup, Rachele M., and Christine Y. Lu. "A Survey of United States Adult Privacy Perspectives and Willingness to Share Real-World Data." *Journal of Clinical and Translational Science* 7, no. 1 (ed 2023): e64. <https://doi.org/10.1017/cts.2023.4>.
39. Hendricks-Sturup, Rachele M., Fang Zhang, and Christine Y. Lu. "A Survey of Research Participants' Privacy-Related Experiences and Willingness to Share Real-World Data with Researchers." *Journal of Personalized Medicine* 12, no. 11 (November 2022): 1922. <https://doi.org/10.3390/jpm12111922>.
40. Heuvel, Tim van den, Javier Castañeda, Arcelia Arrieta, Benedikt Voelker, Ohad Cohen, Margaret Liu, Franck Diaz Garelli, and John Shin. "Generating Real-World Evidence on Diabetes Technology Using the CareLink Personal Data Management System." *Diabetes, Obesity and Metabolism* 26, no. 11 (2024): 4846–53. <https://doi.org/10.1111/dom.15868>.
41. Hi Gin Sung, Han-Heui Park, Gyu-Won Jung, and Ju-Young Shin. "Current Status and Examples of US FDA or EMA's Regulatory Decision Using Real World Data/Real World Evidence." *Yakhak Hoeji* 64, no. 2 (March 23, 2020).
42. "ISPOR 2022-2023 Top 10 HEOR Trends Report." ISPOR, 2022.

<https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends>.

43. Jaksa, Ashley, James Wu, Páll Jónsson, Hans-Georg Eichler, Sarah Vititoe, and Nicolle M Gatto. "Organized Structure of Real-World Evidence Best Practices: Moving from Fragmented Recommendations to Comprehensive Guidance." *Journal of Comparative Effectiveness Research* 10, no. 9 (June 2021): 711–31. <https://doi.org/10.2217/ce-2020-0228>.
44. Jeff Andrews. "Evidence Generation for Screening and Diagnostic Tests and Algorithms," 2019. https://www2.ebhconference.org/previous_editions/2019/posters/Andrews_J.pdf.
45. Jemielita, Thomas, Xiaoyun (Nicole) Li, Thomas Burke, Kai-Li Liaw, Wei Zhou, and Cong Chen. "Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-Small-Cell Lung Cancer Treated With Pembrolizumab." *JCO Clinical Cancer Informatics*, no. 5 (December 2021): 849–58. <https://doi.org/10.1200/CCI.21.00042>.
46. Jiang, Dingfeng, Kun Chen, Saurabh Mukhopadhyay, Nareen Katta, and Lanju Zhang. "Review of Statistical Issues in Pragmatic Clinical Trials in Current Drug Development Environment." In *Contemporary Biostatistics with Biopharmaceutical Applications*, edited by Lanju Zhang, Ding-Geng (Din) Chen, Hongmei Jiang, Gang Li, and Hui Quan, 285–98. ICSA Book Series in Statistics. Cham: Springer International Publishing, 2019. https://doi.org/10.1007/978-3-030-15310-6_16.
47. Jie Chen, Hongbo Yuan, Haijun Tian, and Kristijan Kahler. "Guidance on the Design and Protocol Development of Real-World Studies for Drugs (DRAFT)." Center for Drug Evaluation (CDE) National Medical Products Administration of China, July 2022. [http://www.gdbiost.org/uploads/files/Guidance%20on%20the%20Design%20and%20Protocol%20Development%20of%20Real-World%20Studies\(Draft\).pdf](http://www.gdbiost.org/uploads/files/Guidance%20on%20the%20Design%20and%20Protocol%20Development%20of%20Real-World%20Studies(Draft).pdf).
48. Ji-Hwan Bae, Han-Heui Park, Gyu-Won Jung, Hi Gin Sung, Jiyoung Yang, JungEun Hwang, Dongwon Yoon, Yunha Noh, and Ju-Young Shin. "Establishment of Framework for the Development and Review of Drugs Based on Real-World Data/Real-World Evidence." *약물역학위해관리학회지* 11 (2019): 62–71.
49. Jiyeon Kang. "Real-World Data in Health Technology Assessment: Do We Know It Well Enough?" In *Precision Oncology and Cancer Biomarkers*, Vol. 5. Human Perspectives in Health Sciences and Technology. Springer, 2022.
50. Jormanainen, Vesa. "Valtakunnallisten Kanta-palvelujen käyttöönotto apteekeissa ja

kuntien julkisessa perusterveydenhuollossa vuosina 2010–2016.” *Finnish Journal of eHealth and eWelfare* 11, no. 3 (May 6, 2019): 169–82.
<https://doi.org/10.23996/fjhw.77601>.

51. Katkade, Vaibhav B, Kafi N Sanders, and Kelly H Zou. “Real World Data: An Opportunity to Supplement Existing Evidence for the Use of Long-Established Medicines in Health Care Decision Making.” *Journal of Multidisciplinary Healthcare* 11 (July 2, 2018): 295–304.
<https://doi.org/10.2147/JMDH.S160029>.
52. Kc, Sarin, Lydia Wenxin Lin, Diana Beatriz Samson Bayani, Yaroslava Zemlyanska, Amanda Adler, Jeonghoon Ahn, Kelvin Chan, et al. “What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A Reflection Into the Past and A Way Forward.” *International Journal of Health Policy and Management* 12, no. Issue 1 (December 1, 2023): 1–9.
<https://doi.org/10.34172/ijhpm.2023.6858>.
53. Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, Christina Silcox, Morgan Romine, Kathryn Lallinger, Adam Kroetsch, Huzyfa Fazili, Marta Wosinska, and Mark McClellan. “A Roadmap for Developing Study Endpoints in Real-World Settings.” Duke-Margolis Center for Health Policy, August 28, 2020.
<https://healthpolicy.duke.edu/publications/roadmap-developing-study-endpoints-real-world-settings>.
54. Khosla, Sajan, Robert White, Jesús Medina, Mario Ouwens, Cathy Emmas, Tim Koder, Gary Male, and Sandra Leonard. “Real World Evidence (RWE) – a Disruptive Innovation or the Quiet Evolution of Medical Evidence Generation?” *F1000Research* 7 (August 29, 2018): 111. <https://doi.org/10.12688/f1000research.13585.2>.
55. Klonoff, David C. “The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.” *Journal of Diabetes Science and Technology* 14, no. 2 (March 1, 2020): 345–49. <https://doi.org/10.1177/1932296819832661>.
56. Kraus, V. B., L. S. Simon, J. N. Katz, T. Neogi, D. Hunter, A. Guerhazi, and M. A. Karsdal. “Proposed Study Designs for Approval Based on a Surrogate Endpoint and a Post-Marketing Confirmatory Study under FDA’s Accelerated Approval Regulations for Disease Modifying Osteoarthritis Drugs.” *Osteoarthritis and Cartilage* 27, no. 4 (April 1, 2019): 571–79. <https://doi.org/10.1016/j.joca.2018.11.002>.
57. Kugener, Veronique F., Eric S. Freedland, Kenneth I. Maynard, Omar Aimer, Peggy S. Webster, Maribel Salas, and Maxine Gossell-Williams. “Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities.” *Drug Safety* 44,

- no. 8 (August 1, 2021): 843–52. <https://doi.org/10.1007/s40264-021-01078-8>.
58. Lai, E. C.-C., T.-C. Lin, J. L. Lange, L. Chen, I. C. K. Wong, C.-W. Sing, C.-L. Cheung, S.-C. Shao, and Y.-H. Kao Yang. "Effectiveness of Denosumab for Fracture Prevention in Real-World Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study." *Osteoporosis International* 33, no. 5 (May 1, 2022): 1155–64. <https://doi.org/10.1007/s00198-021-06291-w>.
59. Lauren Elizabeth Eyler Dang. "Development and Application of the Experiment-Selector Cross-Validated Targeted Maximum Likelihood Estimator." University of California, Berkeley, 2023. <https://www.proquest.com/docview/2869145998?pq-origsite=gscholar&fromopenview=true&sourcetype=Dissertations%20&%20Theses>.
60. Li, Wei, Haidong Fan, Jing Tang, Qingyuan Wang, Xu Zhang, and Jaafar A. El-Awady. "Effects of Alloying on Deformation Twinning in High Entropy Alloys." *Materials Science and Engineering: A* 763 (August 19, 2019): 138143. <https://doi.org/10.1016/j.msea.2019.138143>.
61. Ligang Luo, Pingyan Chen, Jianing Di, Jun Wang, and Chunquan Ou. "Guideline on Using Real-World Data to Generate Real-World Evidence (Trial Version)." Center for Drug Evaluation, NMPA, April 2021. <http://www.gdbiost.org/uploads/files/%E3%80%8AGuideline%20on%20Using%20Real-World%20Data%20to%20Generate%20Real-World%20Evidence%E3%80%8B-RWD%E8%AF%95%E8%A1%8C.pdf>.
62. Lim, Robyn, David K. Lee, Pierre Sabourin, John Ferguson, Marilyn Metcalf, Meredith Smith, Solange Corriol-Rohou, et al. "Recognizing That Evidence Is Made, Not Born." *Clinical Pharmacology & Therapeutics* 105, no. 4 (2019): 844–56. <https://doi.org/10.1002/cpt.1317>.
63. Lin, Xiwu, Gang Li, and Hui Quan. "Strategy for Combining Information from Real World Data Sources When Individual Patient Data Are Not Simultaneously Accessible." *Statistics in Biopharmaceutical Research* 14, no. 4 (October 2, 2022): 456–62. <https://doi.org/10.1080/19466315.2022.2063170>.
64. Ling, Albee Y., Rana Jreich, Maria E. Montez-Rath, Zhaoling Meng, Kris Kapphahn, Karen J. Chandross, and Manisha Desai. "Transporting Observational Study Results to a Target Population of Interest Using Inverse Odds of Participation Weighting." *PLOS ONE* 17, no. 12 (December 15, 2022): e0278842. <https://doi.org/10.1371/journal.pone.0278842>.
65. LoCasale, Robert J., Chris L. Pashos, Ben Gutierrez, Nancy A. Dreyer, Toby Collins, Alan

- Calleja, Michael J. Seewald, et al. "Bridging the Gap Between RCTs and RWE Through Endpoint Selection." *Therapeutic Innovation & Regulatory Science* 55, no. 1 (January 1, 2021): 90–96. <https://doi.org/10.1007/s43441-020-00193-5>.
66. Lopez, Marianne Hamilton, Mark B. McClellan, and Gregory Daniel. "Perspectives on Improving Value Assessment With the ISPOR SUITABILITY Checklist." *Value in Health* 27, no. 6 (June 1, 2024): 687–88. <https://doi.org/10.1016/j.jval.2024.04.020>.
67. Lydia Wenxin Lin, Jeonghoon Ahn, Diana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Wandrudee Isaranuwatjai, Sarin KC, et al. "Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia." REALISE Group, November 1, 2020. https://hiper.nus.edu.sg/wp-content/uploads/2021/03/REALISE-Full-guidance-post-feedback_20201211-version-1.1.pdf.
68. Marc Berger, Greg Daniel, Katherine Frank, Adrian Hernandez, Mark McClellan, Sally Okun, Marc Overhage, et al. "A Framework for Regulatory Use of Real-World Evidence." Duke-Margolis Center for Health Policy, September 13, 2017. <https://healthpolicy.duke.edu/publications/framework-regulatory-use-real-world-evidence>.
69. Marc Berger, James Li, William Crown, and Kelly Zou. "ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making," June 7, 2023. <https://doi.org/10.21203/rs.3.rs-3025202/v1>.
70. Milla Kajanne. "Tosielaman Tiedon Hyodyntaminen Sairaalassa -- Tiedolla Johtaminen Ja Sen Kehittaminen Kohti Vaikuttavuusperusteista Terveysthuoltoja," 2021. <https://helda.helsinki.fi/server/api/core/bitstreams/e4b9d9a8-dfcd-4cb9-b58e-8c2ec6e33ef2/content>.
71. Mofid, Sarah, Winona Rei Bolisli, and Thomas C. Kühler. "Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA." *Clinical Therapeutics* 44, no. 2 (February 1, 2022): 306–22. <https://doi.org/10.1016/j.clinthera.2021.12.010>.
72. Neil A Belson. "Emergence of Real World Evidence in Precision Medicine." In *The Road from Nanomedicine to Precision Medicine*, First. Jenny Stanford Publishing, 2020.
73. Neil A. Belson. "FDA's Historical Use of 'Real World Evidence.'" FDLI, 2018. https://heinonline.org/HOL/Page?handle=hein.journals/fdliup2018&div=45&g_sent=1&asa_token=&collection=journals.

74. Nicola Sawalhi-Leckenby, Sofia Fernandes, and Vernon Schabert. "The Evidence Forum: Navigating the Path to Approval and Access: Research Operations for Secondary Use of Clinical Sites' EMR." Evidera, Fall 2019. https://www.evidera.com/wp-content/uploads/2019/10/FINAL_The-Evidence-Forum_Fall_2019.pdf#page=33.
75. Nicole Rodrigues. "Real World Evidence: Impact on Clinical Data." *Data Basics* 25, no. 1 (2019). <https://scdm.org/wp-content/uploads/2019/12/1.pdf#page=18>.
76. Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas Harisson, Adam Aten, Rachel Sherman, Gregory Daniel, and Mark McClellan. "Determining Real-World Data's Fitness for Use and the Role of Reliability." Duke-Margolis Center for Health Policy, September 26, 2019. <https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>.
77. Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, Katherine Frank, Morgan Romine, Adam Kroetsch, Rachel Sherman, Gregory Daniel, and Mark McClellan. "Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility." Duke-Margolis Center for Health Policy, November 25, 2019. <https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world>.
78. Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam Kroetsch, Katherine Frank, Rachel Sherman, Gregory Daniel, and Mark McClellan. "Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness." Duke-Margolis Center for Health Policy, December 19, 2019. <https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product>.
79. Oksen, Dina, Patricia Prince, Emmanuelle Boutmy, Elizabeth M. Garry, Barbara Ellers-Lenz, Adina Estrin, Andreas Johne, Patrice Verpillat, and Nicolle M. Gatto. "Treatment Effectiveness in a Rare Oncology Indication: Lessons from an External Control Cohort Study." *Clinical and Translational Science* 15, no. 8 (2022): 1990–98. <https://doi.org/10.1111/cts.13315>.
80. O'Leary, Colin P., and Matthew A. Cavender. "Emerging Opportunities to Harness Real World Data: An Introduction to Data Sources, Concepts, and Applications." *Diabetes, Obesity and Metabolism* 22, no. S3 (2020): 3–12. <https://doi.org/10.1111/dom.13948>.

81. Olson, William H., and Ibrahim Turkoz. "Up-Front Matching: An Ongoing Recruitment Method for Prospective Observational Studies That Mimics Randomization for Selected Baseline Covariates." *Journal of Biopharmaceutical Statistics*, n.d., 1–14.
<https://doi.org/10.1080/10543406.2024.2373436>.
82. O'Neill, Tyler, Rebecca Miksad, Danelle Miller, Lesley Maloney, Ani John, Carolyn Hiller, and John Hornberger. "ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products." *Value in Health* 22, no. 7 (July 1, 2019): 754–61.
<https://doi.org/10.1016/j.jval.2019.03.020>.
83. Quazi, Sabrina, Claire Narang, Juan C. Espinoza, and Florence T. Bourgeois. "Characteristics and Results of Pediatric Medical Device Studies: 2017–2022." *Pediatrics* 152, no. 3 (August 11, 2023): e2022059842. <https://doi.org/10.1542/peds.2022-059842>.
84. Rachele Hendricks-Sturup and Dixil Francis. "Evidence on Real-World Data and Real-World Evidence As a Driver for Precision Medicine Implementation in Pharmacy Practice." In *Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy*. Springer, Cham, March 23, 2023. https://doi.org/10.1007/978-3-030-50247-8_93-1.
85. Raman, Sudha R., Lesley H. Curtis, Robert Temple, Tomas Andersson, Justin Ezekowitz, Ian Ford, Stefan James, et al. "Leveraging Electronic Health Records for Clinical Research." *American Heart Journal* 202 (August 1, 2018): 13–19.
<https://doi.org/10.1016/j.ahj.2018.04.015>.
86. Raman, Sudha R, Emily C O'Brien, Bradley G Hammill, Adam J Nelson, Laura J Fish, Lesley H Curtis, and Keith Marsolo. "Evaluating Fitness-for-Use of Electronic Health Records in Pragmatic Clinical Trials: Reported Practices and Recommendations." *Journal of the American Medical Informatics Association* 29, no. 5 (May 1, 2022): 798–804.
<https://doi.org/10.1093/jamia/ocac004>.
87. Rebecca Ray, Trevan Locke, and Rachele Hendricks-Sturup. "Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem." Duke-Margolis Center for Health Policy, July 20, 2022.
<https://healthpolicy.duke.edu/publications/aligning-shared-evidentiary-needs-among-payers-and-regulators-real-world-data>.
88. Richard E. Gliklich, Michelle B. Leavy, and Nancy A. Dreyer. "Registries for Evaluating Patient Outcomes: A User's Guide: Addendum 2 - Tools for Registry Interoperability." AHRQ, October 2019.
https://web.archive.org/web/20200506073435id_/https://effectivehealthcare.ahrq.gov/s

ites/default/files/pdf/ehc-registries-users-guide-third-edition-second-addendum.pdf.

89. Robert S. Miller, Kristi Mitchell, Rachel Myslinski, and Josh Rising. "Health Information Technology (IT) and Patient Registries." In *Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User's Guide*, 3rd ed. Rockville, MD: Agency for healthcare Research and Quality, 2019. <https://www.ncbi.nlm.nih.gov/books/NBK551883/>.
90. Roberts, Melissa H., and Gary T. Ferguson. "Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions." *PharmacoEconomics - Open* 5, no. 1 (March 1, 2021): 3–11. <https://doi.org/10.1007/s41669-020-00221-y>.
91. Roig Izquierdo, Marta, Maria Alba Prat Casanovas, Maria Queralt Gorgas Torner, and Caridad Pontes García. "Registro de pacientes y tratamientos de medicamentos hospitalarios en Cataluña: 10 años de datos clínicos." *Medicina Clínica* 154, no. 5 (March 13, 2020): 185–91. <https://doi.org/10.1016/j.medcli.2019.09.009>.
92. Rosenberg, Matthew, Sarah Sheehan, Esther Zhou, Ellen Pinnow, Jessica Burnell, Morgan Romine, and Gerald Dal Pan. "FDA Postmarketing Safety Labeling Changes: What Have We Learned since 2010 about Impacts on Prescribing Rates, Drug Utilization, and Treatment Outcomes." *Pharmacoepidemiology and Drug Safety* 29, no. 9 (2020): 1022–29. <https://doi.org/10.1002/pds.5073>.
93. Rudrapatna, Vivek A., and Atul J. Butte. "Opportunities and Challenges in Using Real-World Data for Health Care." *The Journal of Clinical Investigation* 130, no. 2 (February 3, 2020): 565–74. <https://doi.org/10.1172/JCI129197>.
94. Samson, Sandrine I., Kevin Konty, Wei-Nchih Lee, Tom Quisel, Luca Foschini, David Kerr, Jan Liska, et al. "Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact." *Journal of Diabetes Science and Technology* 15, no. 1 (January 1, 2021): 44–52. <https://doi.org/10.1177/1932296819883340>.
95. Santiago Hasdeu, Ernesto Ruiz, Guadalupe Montero, Daiana Campo, and Eliana Carrasco. "Farmacoepidemiología y Costos Del Tratamiento de La Artritis Reumatoidea En Base a Datos de La Vida Real de La Provincia Argentina de Neuquen: Estudio Descripto (Años 2012-2023)." *Revista De Salud Publica* 30, no. 1 (June 30, 2024). <https://doi.org/10.31052/1853.1180.v30.n1.42890>.
96. Sarri, Grammati, Elisabetta Patorno, Hongbo Yuan, Jianfei (Jeff) Guo, Dimitri Bennett, Xuerong Wen, Andrew R. Zullo, et al. "Framework for the Synthesis of Non-Randomised

- Studies and Randomised Controlled Trials: A Guidance on Conducting a Systematic Review and Meta-Analysis for Healthcare Decision Making." *BMJ Evidence-Based Medicine* 27, no. 2 (April 1, 2022): 109–19. <https://doi.org/10.1136/bmjebm-2020-111493>.
97. Segal J, Levy J, DiStefano M, Sharma, R, Zhang A, Kodavarti N, and Bass E. "Analysis of Requirements for Coverage With Evidence Development (CED) - Topic Refinement." Agency for healthcare Research and Quality, November 2022. <https://effectivehealthcare.ahrq.gov/products/coverage-evidence-development/research-report>.
98. Seifu, Yodit, Margaret Gamalo-Siebers, Friederike M.-S. Barthel, Junjing Lin, Junshan Qiu, Freda Cooner, Shiling Ruan, and Rosalind Walley. "Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review." *Therapeutic Innovation & Regulatory Science* 54, no. 6 (November 1, 2020): 1436–43. <https://doi.org/10.1007/s43441-020-00170-y>.
99. Shapiro, Allison, Benjamin Bradshaw, Sabine Landes, Petra Kammann, Beatrice Bois De Fer, Wei-Nchih Lee, and Robert Lange. "A Novel Digital Approach to Describe Real World Outcomes among Patients with Constipation." *Npj Digital Medicine* 4, no. 1 (February 16, 2021): 1–9. <https://doi.org/10.1038/s41746-021-00391-x>.
100. Stewart, Mark, Andrew D. Norden, Nancy Dreyer, Henry Joe Henk, Amy P. Abernethy, Elizabeth Chrischilles, Lawrence Kushi, et al. "An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer." *JCO Clinical Cancer Informatics*, no. 3 (December 2019): 1–15. <https://doi.org/10.1200/CCI.18.00155>.
101. Sung, Hi Gin, Han-Heui Park, Gyu-Won Jung, and Ju-Young Shin. "Current Status and Examples of US FDA or EMA's Regulatory Decision Using Real World Data/Real World Evidence." *Yakhak Hoeji* 64, no. 2 (April 30, 2020): 136–55. <https://doi.org/10.17480/psk.2020.64.2.136>.
102. Tan, George S. Q., Erica K. Sloan, Pete Lambert, Carl M. J. Kirkpatrick, and Jenni Ilomäki. "Drug Repurposing Using Real-World Data." *Drug Discovery Today* 28, no. 1 (January 1, 2023): 103422. <https://doi.org/10.1016/j.drudis.2022.103422>.
103. Thakur, Sayanta. "Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?" *Indian Journal of Surgical Oncology*, June 21, 2023. <https://doi.org/10.1007/s13193-023-01784-y>.
104. Timbie, Justin W, Alice Y Kim, Lawrence Baker, Rosemary Li, and Thomas

- W Concannon. "Lessons on the Use of Real-World Data in Medical Device Research: Findings from the National Evaluation System for Health Technology Test-Cases." *Journal of Comparative Effectiveness Research* 13, no. 9 (September 2024): e240078. <https://doi.org/10.57264/cer-2024-0078>.
105. Varnai, Peter, Anoushka Davé, Kristine Farla, Anke Nooijen, and Liana Petrosova. "The Evidence REVEAL Study: Exploring the Use of Real-World Evidence and Complex Clinical Trial Design by the European Pharmaceutical Industry." *Clinical Pharmacology & Therapeutics* 110, no. 5 (2021): 1180–89. <https://doi.org/10.1002/cpt.2103>.
106. Villines, Todd C, Mark J Cziraky, and Alpesh N Amin. "Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-World Evidence in Clinical Decision Making." *Clinical Medicine Insights: Cardiology* 14 (January 1, 2020): 1179546820953410. <https://doi.org/10.1177/1179546820953410>.
107. W. Nicholson Price II. "Drug Approval in a Learning Health System." *Minnesota Law Review* 102, no. 6 (June 2018): 2413–62.
108. Wang, Jun, Jie Chen, Jun Zhao, Ying Wu, Xiaona Xin, and Pingyan Chen. "Establishment of RWS Guidance Reflecting Contributions of China to Regulatory Science." *Journal of Biopharmaceutical Statistics*, March 17, 2024. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>.
109. Wang, Shirley V., Sushama Kattinakere Sreedhara, and Sebastian Schneeweiss. "Reproducibility of Real-World Evidence Studies Using Clinical Practice Data to Inform Regulatory and Coverage Decisions." *Nature Communications* 13, no. 1 (August 31, 2022): 5126. <https://doi.org/10.1038/s41467-022-32310-3>.
110. Webster, Jonathan, and B. Douglas Smith. "The Case for Real-World Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia." *Clinical Therapeutics* 41, no. 2 (February 1, 2019): 336–49. <https://doi.org/10.1016/j.clinthera.2018.12.013>.
111. Weng, Xinyu. "Real-World Evidence Approach to Traditional Herbal Medicinal Products." *Drug Discovery Today* 23, no. 7 (July 2018): 1321–23. <https://doi.org/10.1016/j.drudis.2018.05.008>.
112. Wise, John, Angeli Möller, David Christie, Dipak Kalra, Elia Brodsky, Evelina Georgieva, Greg Jones, et al. "The Positive Impacts of Real-World Data on the Challenges Facing the Evolution of Biopharma." *Drug Discovery Today* 23, no. 4 (April 1, 2018): 788–801. <https://doi.org/10.1016/j.drudis.2018.01.034>.

113. Xia, Andrew D., Caroline P. Schaefer, Agota Szende, Elke Jahn, and Matthew J. Hirst. "RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design." *Drugs - Real World Outcomes* 6, no. 4 (December 1, 2019): 193–203. <https://doi.org/10.1007/s40801-019-00167-6>.
114. Yang, Hee-Soo, So-Young Kim, and Jong-Hyock Park. "Development and Utilization of Drug Lifecycle Data in the United States, Japan, and Europe." *Journal of Health Informatics and Statistics* 48, no. 2 (May 31, 2023): 148–56. <https://doi.org/10.21032/jhis.2023.48.2.148>.
115. Zhu, Ming, Saranya Sridhar, Rosalind Hollingsworth, Ayman Chit, Tammy Kimball, Kerry Murmello, Michael Greenberg, Sanjay Gurunathan, and Josh Chen. "Hybrid Clinical Trials to Generate Real-World Evidence: Design Considerations from a Sponsor's Perspective." *Contemporary Clinical Trials* 94 (July 1, 2020): 105856. <https://doi.org/10.1016/j.cct.2019.105856>.
116. Zhu, Rui, Bianca Vora, Sujatha Menon, Islam Younis, Gaurav Dwivedi, Zhaoling Meng, Amita Datta-Mannan, et al. "Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval—An Industry Perspective." *Clinical Pharmacology & Therapeutics* n/a, no. n/a. Accessed September 12, 2023. <https://doi.org/10.1002/cpt.2988>.
117. Zura, Robert, Debra E. Irwin, Christina D. Mack, Molly L. Aldridge, and John I. Mackowiak. "Real-World Evidence: A Primer." *Journal of Orthopaedic Trauma* 35 (March 2021): S1. <https://doi.org/10.1097/BOT.0000000000002037>.
118. Сергеевич, Колбин Алексей, and Белоусов Дмитрий Юрьевич. "КИТАЙСКИЙ ОПЫТ ПО ИСПОЛЬЗОВАНИЮ ДОКАЗАТЕЛЬСТВ, ПОЛУЧЕННЫХ НА ОСНОВЕ ДАННЫХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ В ПРОЦЕССЕ РАЗРАБОТКИ, ИССЛЕДОВАНИЯ И ОЦЕНКИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ." *Реальная клиническая практика: данные и доказательства* 2, no. 1 (2022): 17–27.

Characterizing RWD Quality and Relevancy for Regulatory Purposes

“The Data Quality Paper” | Published October 2018

1. Alobaida, Muath, Abdullah Alrumayh, Ayodipupo S Oguntade, Faez Al-Amodi, and Mwangi Bwalya. “Cardiovascular Safety and Superiority of Anti-Obesity Medications.” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 14 (July 13, 2021): 3199–3208. <https://doi.org/10.2147/DMSO.S311359>.
2. Bando, H., E. Tajima, Y. Aoyagi, D. Ng, K. Mizuguchi, M. Suzuki, Y. Takeda, et al. “The Emerging Role of Real-World Data in Oncology Care in Japan.” *ESMO Real World Data and Digital Oncology* 2 (December 1, 2023): 100005. <https://doi.org/10.1016/j.esmorw.2023.100005>.
3. Beyrer, Julie. “Regulatory Acceptable Real-World Effectiveness Endpoints: How Clarity Can Best Be Achieved in the United States.” Ph.D., Indiana University - Purdue University Indianapolis, 2023. <https://www.proquest.com/docview/2908925189/abstract/2FBBFAB790144CA3PQ/1>.
4. Beyrer, Julie, Hamed Abedtash, Kenneth Hornbuckle, and James F Murray. “A Review of Stakeholder Recommendations for Defining Fit-for-Purpose Real-World Evidence Algorithms.” *Journal of Comparative Effectiveness Research* 11, no. 7 (May 2022): 499–511. <https://doi.org/10.2217/ce-2022-0006>.
5. Bhatt, Arun. “Data Quality – The Foundation of Real-World Studies.” *Perspectives in Clinical Research* 14, no. 2 (2023): 92–94. https://doi.org/10.4103/picr.picr_12_23.
6. Bourla, Ariel B., and Neal J. Meropol. “Bridging the Divide between Clinical Research and Clinical Care in Oncology: An Integrated Real-World Evidence Generation Platform.” *DIGITAL HEALTH* 7 (January 1, 2021): 20552076211059975. <https://doi.org/10.1177/20552076211059975>.
7. Brown, Jeremy P., Ian J. Douglas, Shahid Hanif, Robert M. A. Thwaites, and Andrew Bate. “Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.” *Value in Health* 24, no. 9 (September 1, 2021): 1241–44. <https://doi.org/10.1016/j.jval.2021.03.020>.
8. Burcu, Mehmet, Nancy A. Dreyer, Jessica M. Franklin, Michael D. Blum, Cathy W. Critchlow, Eleanor M. Perfetto, and Wei Zhou. “Real-World Evidence to Support Regulatory Decision-Making for Medicines: Considerations for External Control Arms.” *Pharmacoepidemiology and Drug Safety* 29, no. 10 (2020): 1228–35. <https://doi.org/10.1002/pds.4975>.
9. Burns, Leah, Nadege Le Roux, Robert Kalesnik-Orszulak, Jennifer Christian, Mathias

- Hukkelhoven, Frank Rockhold, and John O'Donnell. "Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World." *Clinical Therapeutics* 44, no. 3 (March 1, 2022): 420–37. <https://doi.org/10.1016/j.clinthera.2022.01.012>.
10. Castellanos, Emily H., Brett K. Wittmershaus, and Sheenu Chandwani. "Raising the Bar for Real-World Data in Oncology: Approaches to Quality Across Multiple Dimensions." *JCO Clinical Cancer Informatics*, no. 8 (March 2024): e2300046. <https://doi.org/10.1200/CCI.23.00046>.
 11. Curtis, Lesley H., Oriol Sola-Morales, Julien Heidt, Patrick Saunders-Hastings, Laura Walsh, Deborah Casso, Susan Oliveria, et al. "Regulatory and HTA Considerations for Development of Real-World Data Derived External Controls." *Clinical Pharmacology & Therapeutics* n/a, no. n/a. Accessed June 6, 2023. <https://doi.org/10.1002/cpt.2913>.
 12. Daniel, Gregory. "Building Trust in RWE Will Support Clearer Regulatory Uses." *Therapeutic Innovation & Regulatory Science* 53, no. 4 (July 1, 2019): 417–19. <https://doi.org/10.1177/2168479019859948>.
 13. Dreyer, Nancy A., Christina D. Mack, Robert B. Anderson, Edward M. Wojtys, Elliott B. Hershman, and Allen Sills. "Lessons on Data Collection and Curation From the NFL Injury Surveillance Program." *Sports Health* 11, no. 5 (September 1, 2019): 440–45. <https://doi.org/10.1177/1941738119854759>.
 14. "FDA-NIH Terminology for Clinical Research: Glossary of Terms and Definitions." FDA-NIH Clinical Research Working Group, May 2024. https://osp.od.nih.gov/wp-content/uploads/2024/05/Glossary-Terms-for-RFI_Final_Draft.pdf.
 15. Fleurence, Rachael L., Seamus Kent, Blythe Adamson, James Tcheng, Ran Balicer, Joseph S. Ross, Kevin Haynes, et al. "Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force." *Value in Health* 27, no. 6 (June 1, 2024): 692–701. <https://doi.org/10.1016/j.jval.2024.01.019>.
 16. Franklin, Jessica M., Robert J. Glynn, David Martin, and Sebastian Schneeweiss. "Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making." *Clinical Pharmacology & Therapeutics* 105, no. 4 (2019): 867–77. <https://doi.org/10.1002/cpt.1351>.
 17. Gatto, Nicolle M., Ulka B. Campbell, Emily Rubinstein, Ashley Jaksa, Pattra Mattox, Jingping Mo, and Robert F. Reynolds. "The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework." *Clinical Pharmacology & Therapeutics* 111, no. 1 (2022): 122–34. <https://doi.org/10.1002/cpt.2466>.

18. Girman, Cynthia J., Mary E. Ritchey, and Vincent Lo Re. "Real-world Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-making for Drug and Biological Products." *Pharmacoepidemiology and Drug Safety* 31, no. 7 (July 2022): 717–20. <https://doi.org/10.1002/pds.5444>.
19. Girman, Cynthia J., Mary E. Ritchey, Wei Zhou, and Nancy A. Dreyer. "Considerations in Characterizing Real-world Data Relevance and Quality for Regulatory Purposes: A Commentary." *Pharmacoepidemiology and Drug Safety* 28, no. 4 (April 2019): 439–42. <https://doi.org/10.1002/pds.4697>.
20. Gregory Daniel, Christina Silcox, Jonathan Bryan, Mark McClellan, Morgan Romine, and Katherine Frank. "Characterizing RWD Quality and Relevancy for Regulatory Purposes." Duke-Margolis Center for Health Policy, October 1, 2018. <https://healthpolicy.duke.edu/publications/characterizing-rwd-quality-and-relevancy-regulatory-purposes-0>.
21. Gressler, Laura Elisabeth. "The Creation of Objective Performance Criteria and Generation of Predictive Models among Medical Devices in a Vascular Space." Ph.D., University of Maryland, Baltimore, 2021. <https://www.proquest.com/docview/2537953650/abstract/5983EFA19019497EPQ/1>.
22. Gressler, Laura Elisabeth, this link will open in a new window Link to external site, Danica Marinac-Dabic, Susan dosReis, Philip Goodney, this link will open in a new window Link to external site, C. Daniel Mullins, and Fadia Shaya. "Creation of Objective Performance Criteria among Medical Devices." *BMJ Surgery, Interventions, & Health Technologies* 4, no. 1 (August 2022): e000106. <https://doi.org/10.1136/bmjst-2021-000106>.
23. Hanson, Gillian, Tanuja Chitnis, Mitzi J Williams, Ryan William Gan, Laura Julian, Kieran Mace, Jenny Chia, et al. "Generating Real-World Data from Health Records: Design of a Patient-Centric Study in Multiple Sclerosis Using a Commercial Health Records Platform." *JAMIA Open* 5, no. 1 (April 1, 2022): ooab110. <https://doi.org/10.1093/jamiaopen/ooab110>.
24. He, Weili, Yixin Fang, Hongwei Wang, and Ivan Chan. "Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management." *Statistics in Biopharmaceutical Research* 0, no. 0 (May 14, 2021): 1–12. <https://doi.org/10.1080/19466315.2021.1927827>.
25. He, Weili, Zuoyi Zhang, and Sai Dharmarajan. "Assessment of Fit-for-Use Real-World Data Sources and Applications." In *Real-World Evidence in Medical Product Development*, edited by Weili He, Yixin Fang, and Hongwei Wang, 45–61. Cham: Springer International Publishing, 2023. https://doi.org/10.1007/978-3-031-26328-6_4.

26. Heuvel, Tim van den, Javier Castañeda, Arcelia Arrieta, Benedikt Voelker, Ohad Cohen, Margaret Liu, Franck Diaz Garelli, and John Shin. "Generating Real-World Evidence on Diabetes Technology Using the CareLink Personal Data Management System." *Diabetes, Obesity and Metabolism* 26, no. 11 (2024): 4846–53. <https://doi.org/10.1111/dom.15868>.
27. Hou, Jue, Rachel Zhao, Jessica Gronsbell, Brett K. Beaulieu-Jones, Griffin Webber, Thomas Jemielita, Shuyan Wan, et al. "Harnessing Electronic Health Records for Real-World Evidence." arXiv, November 29, 2022. <https://doi.org/10.48550/arXiv.2211.16609>.
28. Hou, Jue, Rachel Zhao, Jessica Gronsbell, Yucong Lin, Clara-Lea Bonzel, Qingyi Zeng, Sinian Zhang, et al. "Generate Analysis-Ready Data for Real-World Evidence: Tutorial for Harnessing Electronic Health Records With Advanced Informatic Technologies." *Journal of Medical Internet Research* 25, no. 1 (May 25, 2023): e45662. <https://doi.org/10.2196/45662>.
29. Jackson, Michael L., Raj Manickam, Dan Derieg, Saurabh Gombar, and Yen S. Low. "Quantifying Fit-for-Purpose in Real World Data: Data Grading and FitQ Scores." medRxiv, February 5, 2024. <https://doi.org/10.1101/2024.02.02.24302239>.
30. Jennifer R. Popovic. "Real-World Data as Real-World Evidence: Establishing the Meaning of Data as a Prerequisite to Determining Secondary-Use Value." PharaSUG2019, 2019. <https://www.lexjansen.com/pharmasug/2019/RW/PharmaSUG-2019-RW-310.pdf>.
31. Kugener, Veronique F., Eric S. Freedland, Kenneth I. Maynard, Omar Aimer, Peggy S. Webster, Maribel Salas, and Maxine Gossell-Williams. "Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities." *Drug Safety* 44, no. 8 (August 1, 2021): 843–52. <https://doi.org/10.1007/s40264-021-01078-8>.
32. L. (Luuk) Bongers. "Including Children with High-Grade CNS Tumors in Existing Labels: The Possibilities of Real-World Evidence." Utrecht University, 2024. <https://studenttheses.uu.nl/bitstream/handle/20.500.12932/45785/Including%20Children%20with%20High%20Grade%20CNS%20Tumors%20in%20Existing%20Labels%20The%20Possibilities%20of%20Real%20World%20Evidence.pdf?sequence=1>.
33. Lesley Curtis, Jeffrey S Brown, John Laschinger, Aaron Lottes, Keith Marsolo, Frederick A. Masoudi, Joseph S Ross, et al. "National Evaluation System for Health Technology Coordinating Center (NESTcc) Data Quality Framework." NEST Coordinating Center, February 2020. <https://mdic.org/wp-content/uploads/2020/02/NESTcc-Data-Quality-Framework.pdf>.
34. Levenson, Mark, Weili He, Li Chen, Sai Dharmarajan, Rima Izem, Zhaoling Meng, Herbert Pang, and Frank Rockhold. "Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development." *Statistics in*

Biopharmaceutical Research 0, no. 0 (September 6, 2022): 1–8.
<https://doi.org/10.1080/19466315.2022.2120533>.

35. Ligang Luo, Pingyan Chen, Jianing Di, Jun Wang, and Chunquan Ou. “Guideline on Using Real-World Data to Generate Real-World Evidence (Trial Version).” Center for Drug Evaluation, NMPA, April 2021.
<http://www.gdbiost.org/uploads/files/%E3%80%8AGuideline%20on%20Using%20Real-World%20Data%20to%20Generate%20Real-World%20Evidence%E3%80%8B-RWD%E8%AF%95%E8%A1%8C.pdf>.
36. Lopez, Marianne Hamilton, Mark B. McClellan, and Gregory Daniel. “Perspectives on Improving Value Assessment With the ISPOR SUIABILITY Checklist.” *Value in Health* 27, no. 6 (June 1, 2024): 687–88. <https://doi.org/10.1016/j.jval.2024.04.020>.
37. Marc Berger, James Li, William Crown, and Kelly Zou. “ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making,” June 7, 2023. <https://doi.org/10.21203/rs.3.rs-3025202/v1>.
38. Marsolo, Keith, Lesley Curtis, Laura Qualls, Jennifer Xu, Yinghong Zhang, Thomas Phillips, C. Larry Hill, et al. “Assessing the Harmonization of Structured Electronic Health Record Data to Reference Terminologies and Data Completeness through Data Provenance.” *Learning Health Systems* n/a, no. n/a (n.d.): e10468.
<https://doi.org/10.1002/lrh2.10468>.
39. Muntner, Paul, Rohini K. Hernandez, Shia T. Kent, James E. Browning, David T. Gilbertson, Kathleen E. Hurwitz, Susan S. Jick, et al. “Staging and Clean Room: Constructs Designed to Facilitate Transparency and Reduce Bias in Comparative Analyses of Real-World Data.” *Pharmacoepidemiology and Drug Safety* 33, no. 3 (2024): e5770.
<https://doi.org/10.1002/pds.5770>.
40. Okun, Sally. “The Missing Reality of Real Life in Real-World Evidence.” *Clinical Pharmacology & Therapeutics* 106, no. 1 (2019): 136–38. <https://doi.org/10.1002/cpt.1465>.
41. O’Leary, Colin P., and Matthew A. Cavender. “Emerging Opportunities to Harness Real World Data: An Introduction to Data Sources, Concepts, and Applications.” *Diabetes, Obesity and Metabolism* 22, no. S3 (2020): 3–12. <https://doi.org/10.1111/dom.13948>.
42. O’Neill, Tyler, Rebecca Miksad, Danelle Miller, Lesley Maloney, Ani John, Carolyn Hiller, and John Hornberger. “ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.” *Value in Health* 22, no. 7 (July 1, 2019): 754–61.
<https://doi.org/10.1016/j.jval.2019.03.020>.

43. Purpura, Christina A., Elizabeth M. Garry, Nicholaas Honig, Abigail Case, and Jeremy A. Rassen. "The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications." *Clinical Pharmacology & Therapeutics* 111, no. 1 (2022): 135–44. <https://doi.org/10.1002/cpt.2474>.
44. Rachael L. DiSantostefano, Erica A Voss, and Clair Blacketer. "‘Fake News’ in the Rush to Inform on COVID-19: How Research Retraction Can Inform Best Practices for Real-World Data Quality and Reporting." Janssen Research and Development, 2020. https://www.ohdsi.org/wp-content/uploads/2020/10/DiSantostefano-Abstract_COVID19-Retractions-Inform-RWD-Quality-and-Reporting-Standards_2020symposium.pdf.
45. Raman, Sudha R, Emily C O’Brien, Bradley G Hammill, Adam J Nelson, Laura J Fish, Lesley H Curtis, and Keith Marsolo. "Evaluating Fitness-for-Use of Electronic Health Records in Pragmatic Clinical Trials: Reported Practices and Recommendations." *Journal of the American Medical Informatics Association* 29, no. 5 (May 1, 2022): 798–804. <https://doi.org/10.1093/jamia/ocac004>.
46. Rivera, Donna R., Henry J. Henk, Elizabeth Garrett-Mayer, Jennifer B. Christian, Andrew J. Belli, Suanna S. Bruinooge, Janet L. Espirito, et al. "The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies." *Clinical Pharmacology & Therapeutics* 111, no. 1 (2022): 283–92. <https://doi.org/10.1002/cpt.2453>.
47. Sola-Morales, Oriol, Lesley H. Curtis, Julien Heidt, Laura Walsh, Deborah Casso, Susan Oliveria, Patrick Saunders-Hastings, et al. "Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory & HTA Decisions." *Clinical Pharmacology & Therapeutics* n/a, no. n/a. Accessed June 6, 2023. <https://doi.org/10.1002/cpt.2914>.
48. Solà-Morales, Oriol, Katla Sigurðardóttir, Ron Akehurst, Linda A. Murphy, Jorge Mestre-Ferrandiz, David Cunningham, and Gérard de Pouvourville. "Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making." *Value in Health, Using Real-World Data in the Health Technology Assessment of Pharmaceuticals*, 26, no. 4, Supplement (April 1, 2023): 32–42. <https://doi.org/10.1016/j.jval.2023.02.012>.
49. Tadrous, Mina, Theresa Aves, Christine Fahim, Jessica Riad, Nicole Mittmann, Daniel Prieto-Alhambra, Donna R. Rivera, et al. "Development of a Canadian Guidance for Reporting Real-World Evidence for Regulatory and Health-Technology Assessment (HTA) Decision-Making." *Journal of Clinical Epidemiology* 176 (December 1, 2024): 111545. <https://doi.org/10.1016/j.jclinepi.2024.111545>.

50. Walters, Kellie M, Marshall Clark, Sofia Dard, Stephanie S Hong, Elizabeth Kelly, Kristin Kostka, Adam M Lee, et al. "National COVID Cohort Collaborative Data Enhancements: A Path for Expanding Common Data Models." *Journal of the American Medical Informatics Association* 32, no. 2 (February 1, 2025): 391–97. <https://doi.org/10.1093/jamia/ocae299>.
51. Wang, Jun, Jie Chen, Jun Zhao, Ying Wu, Xiaona Xin, and Pingyan Chen. "Establishment of RWS Guidance Reflecting Contributions of China to Regulatory Science." *Journal of Biopharmaceutical Statistics*, March 17, 2024. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>.
52. Wang, Shirley V, and Sebastian Schneeweiss. "A Framework for Visualizing Study Designs and Data Observability in Electronic Health Record Data." *Clinical Epidemiology* 14 (April 29, 2022): 601–8. <https://doi.org/10.2147/CLEP.S358583>.
53. 章太郎前田, 香苗東郷, 武蔵石黒, 貴之井上, 武彦坂本, 公寿菅野, and 充弘近藤. "本邦の医薬品開発におけるビッグデータ・リアルワールドデータの利活用に関する実態調査 —日本製薬工業協会加盟各社に対するアンケート調査—." *臨床薬理* 50, no. 4 (2019): 167–75. <https://doi.org/10.3999/jscpt.50.167>.
54. 雅俊谷川, 健一中野, 吉博青柳, and 英人横井. "「医療情報システム」における電磁的記録の薬事利用への対応 —コンピュータ化システムの品質マネジメント—." *医療情報学* 41, no. 3 (2021): 143–53. <https://doi.org/10.14948/jami.41.143>.
55. 香苗東郷, 真也川松, 亮木口, and 康彦今井. "医薬品開発におけるリアルワールドデータ活用への期待 —製薬企業の視点より—." *薬剤疫学* 24, no. 1 (2019): 19–30. <https://doi.org/10.3820/jjpe.24.19>.

Determining Real-World Data's Fitness for Use and the Role of Reliability

"The Data Reliability Paper" | Published September 2019

1. Al-Sahab, B., Leviton, A., Loddenkemper, T., Paneth, N., & Zhang, B. (2024). Biases in Electronic Health Records Data for Generating Real-World Evidence: An Overview. *Journal of Healthcare Informatics Research*, 8(1), 121–139. <https://doi.org/10.1007/s41666-023-00153-2>
2. Antunes, C. P. (2021). *A Regulação dos dispositivos de recolha e processamento de dados em saúde* [masterThesis]. <https://repositorio.ul.pt/handle/10451/52892>
3. Backenroth, D., Royce, T., Pinheiro, J., Samant, M., & Humblet, O. (2023). Considerations for pooling real-world data as a comparator cohort to a single arm trial: A simulation study on assessment of heterogeneity. *BMC Medical Research Methodology*, 23(1), 193. <https://doi.org/10.1186/s12874-023-02002-7>
4. *Best Practices For Evaluating The Relevance And Quality Of RWD*. (n.d.). Retrieved March 13, 2023, from <https://www.clinicalleader.com/doc/best-practices-for-evaluating-the-relevance-and-quality-of-rwd-0001>
5. Beyrer, J., Abedtash, H., Hornbuckle, K., & Murray, J. F. (2022). A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*, 11(7), 499–511. <https://doi.org/10.2217/cer-2022-0006>
6. Boikos, C., Imran, M., De Lusignan, S., Ortiz, J. R., Patriarca, P. A., & Mansi, J. A. (2022). Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines*, 10(5), Article 5. <https://doi.org/10.3390/vaccines10050727>
7. Boyle, J. M., Hegarty, G., Frampton, C., Harvey-Jones, E., Dodkins, J., Beyer, K., George, G., Sullivan, R., Booth, C., & Aggarwal, A. (2021). Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study. *European Journal of Cancer*, 155, 136–144. <https://doi.org/10.1016/j.ejca.2021.07.001>
8. Burns, L., Kalesnik-Orszulak, R., Spring, R., Zeegers, F., Rutstein, M., Hukkelhoven, M., Wruck, L., & O'Donnell, J. (2022). Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies. *Advances in Therapy*, 39(10), 4772–4778. <https://doi.org/10.1007/s12325-022-02257-4>
9. Castellanos, E. H., Wittmershaus, B. K., & Chandwani, S. (2024). Raising the Bar for Real-

- World Data in Oncology: Approaches to Quality Across Multiple Dimensions. *JCO Clinical Cancer Informatics*, 8, e2300046. <https://doi.org/10.1200/CCI.23.00046>
10. Chen, J., Li, X. (Nicole), Lu, C. (Cindy), Yuan, S., Yung, G., Ye, J., Tian, H., & Lin, J. (n.d.). Considerations for master protocols using external controls. *Journal of Biopharmaceutical Statistics*, 1–23. <https://doi.org/10.1080/10543406.2024.2311248>
 11. Clay, I., Cormack, F., Fedor, S., Foschini, L., Gentile, G., Hoof, C. van, Kumar, P., Lipsmeier, F., Sano, A., Smarr, B., Vandendriessche, B., & Luca, V. D. (2022). Measuring Health-Related Quality of Life With Multimodal Data: Viewpoint. *Journal of Medical Internet Research*, 24(5), e35951. <https://doi.org/10.2196/35951>
 12. Cocoros, N. M., Arlett, P., Dreyer, N. A., Ishiguro, C., Iyasu, S., Sturkenboom, M., Zhou, W., & Toh, S. (2021). The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. *Clinical Pharmacology & Therapeutics*, 109(5), 1189–1196. <https://doi.org/10.1002/cpt.2045>
 13. Crane, G., Lim, J. C. W., Gau, C.-S., Xie, J., & Chu, L. (2022). The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: Expert panel recommendations. *Current Medical Research and Opinion*, 38(9), 1543–1551. <https://doi.org/10.1080/03007995.2022.2096354>
 14. Csoke, E., Landes, S., Francis, M. J., Ma, L., Teotico Pohlhaus, D., & Anquez-Traxler, C. (2022). How can real-world evidence aid decision making during the life cycle of nonprescription medicines? *Clinical and Translational Science*, 15(1), 43–54. <https://doi.org/10.1111/cts.13129>
 15. Daubner-Bendes, R., Kovács, S., Niewada, M., Huic, M., Drummond, M., Ciani, O., Blankart, C. R., Mandrik, O., Torbica, A., Yfantopoulos, J., Petrova, G., Holownia-Voloskova, M., Taylor, R. S., Al, M., Piniashko, O., Lorenzovici, L., Tarricone, R., Zemlányi, A., & Kaló, Z. (2021). Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Frontiers in Public Health*, 8. <https://www.frontiersin.org/articles/10.3389/fpubh.2020.612410>
 16. Derman, B. A., Belli, A. J., Battiwalla, M., Hamadani, M., Kansagra, A., Lazarus, H. M., & Wang, C.-K. (2022). Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. *Blood Reviews*, 53, 100913. <https://doi.org/10.1016/j.blre.2021.100913>
 17. Dreyer, N. A., Hall, M., & Christian, J. B. (2020). Modernizing Regulatory Evidence with Trials and Real-World Studies. *Therapeutic Innovation & Regulatory Science*, 54(5), 1112–1115. <https://doi.org/10.1007/s43441-020-00131-5>

18. *External Controls in Research: The “What, Why and How.”* (2021, May 27). UBC.
<https://ubc.com/external-controls-in-research/>
19. Fleurence, R. L., Kent, S., Adamson, B., Tcheng, J., Balicer, R., Ross, J. S., Haynes, K., Muller, P., Campbell, J., Bouée-Benhamiche, E., García Martí, S., & Ramsey, S. (2024). Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force. *Value in Health*, 27(6), 692–701. <https://doi.org/10.1016/j.jval.2024.01.019>
20. Goldsack, J. C., Dowling, A. V., Samuelson, D., Patrick-Lake, B., & Clay, I. (2021). Evaluation, Acceptance, and Qualification of Digital Measures: From Proof of Concept to Endpoint. *Digital Biomarkers*, 5(1), 53–64. <https://doi.org/10.1159/000514730>
21. Gressler, L. E., Avila-Tang, E., Mao, J., Avalos-Pacheco, A., Shaya, F. T., Torosyan, Y., Liebeskind, A., Kinard, M., Mack, C. D., Normand, S.-L., Ritchey, M. E., & Marinac-Dabic, D. (2024). Data sources and applied methods for paclitaxel safety signal discernment. *Frontiers in Cardiovascular Medicine*, 10. <https://doi.org/10.3389/fcvm.2023.1331142>
22. Gressler, L. E., Marinac-Dabic, D., Resnic, F. S., Williams, S., Yang, K., Weichold, F., Avila-Tang, E., Mack, C., Coplan, P., Panagiotou, O. A., & Pappas, G. (2024). A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks. *Therapeutic Innovation & Regulatory Science*. <https://doi.org/10.1007/s43441-024-00680-z>
23. He, W., Fang, Y., Wang, H., & Chan, I. (2023). Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*, 15(1), 57–68.
<https://doi.org/10.1080/19466315.2021.1927827>
24. He, W., Zhang, Z., & Dharmarajan, S. (2023). Assessment of Fit-for-Use Real-World Data Sources and Applications. In W. He, Y. Fang, & H. Wang (Eds.), *Real-World Evidence in Medical Product Development* (pp. 45–61). Springer International Publishing.
https://doi.org/10.1007/978-3-031-26328-6_4
25. Hiramatsu, K., Barrett, A., Miyata, Y., & PhRMA Japan Medical Affairs Committee Working Group 1. (2021). Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan. *Drugs - Real World Outcomes*, 8(4), 459–480. <https://doi.org/10.1007/s40801-021-00266-3>
26. Inan, O. T., Tenaerts, P., Prindiville, S. A., Reynolds, H. R., Dizon, D. S., Cooper-Arnold, K., Turakhia, M., Pletcher, M. J., Preston, K. L., Krumholz, H. M., Marlin, B. M., Mandl, K. D., Klasnja, P., Spring, B., Iturriaga, E., Campo, R., Desvigne-Nickens, P., Rosenberg, Y.,

- Steinhubl, S. R., & Califf, R. M. (2020). Digitizing clinical trials. *Npj Digital Medicine*, 3(1), Article 1. <https://doi.org/10.1038/s41746-020-0302-y>
27. Jackson, M. L., Manickam, R., Derieg, D., Gombar, S., & Low, Y. S. (2024). *Quantifying Fit-for-Purpose in Real World Data: Data Grading and FitQ Scores* (p. 2024.02.02.24302239). medRxiv. <https://doi.org/10.1101/2024.02.02.24302239>
28. Jaksá, A., Arena, P. J., Chan, K. K. W., Ben-Joseph, R. H., Jónsson, P., & Campbell, U. B. (2022). Transferability of real-world data across borders for regulatory and health technology assessment decision-making. *Frontiers in Medicine*, 9. <https://www.frontiersin.org/articles/10.3389/fmed.2022.1073678>
29. Jaksá, A., Wu, J., Jónsson, P., Eichler, H.-G., Vititoe, S., & Gatto, N. M. (2021). Organized structure of real-world evidence best practices: Moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*, 10(9), 711–731. <https://doi.org/10.2217/cer-2020-0228>
30. Jiu, L., Hartog, M., Wang, J., Vreman, R. A., Klungel, O. H., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Tools for assessing quality of studies investigating health interventions using real-world data: A literature review and content analysis. *BMJ Open*, 14(2), e075173. <https://doi.org/10.1136/bmjopen-2023-075173>
31. Kataria, S., & Ravindran, V. (2022). Harnessing of real-world data and real-world evidence using digital tools: Utility and potential models in rheumatology practice. *Rheumatology*, 61(2), 502–513. <https://doi.org/10.1093/rheumatology/keab674>
32. Kaushal D. Desai, Matthew W. Reynolds, Jennifer B. Christian, & Hossein Estiri. (2021). Fit-for-Purpose Real-World Data Assessments in Oncology: A Call for Cross-Stakeholder Collaboration. *Value and Outcomes Spotlight*, 7(3). <https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/expanding-the-value-conversation/fit-for-purpose-real-world-data-assessments-in-oncology-a-call-for-cross-stakeholder-collaboration>
33. Kehoe, L., Locke, T., McClellan, M., Landray, M., Hernandez, A., & Okun, S. (2024). Overcoming the barriers to better evidence generation from clinical trials. *Trials*, 25(1), 614. <https://doi.org/10.1186/s13063-024-08460-8>
34. Klimek, P., Baltic, D., Brunner, M., Degelsegger-Marquez, A., Garhöfer, G., Gouya-Lechner, G., Herzog, A., Jilma, B., Kähler, S., Mikl, V., Mraz, B., Ostermann, H., Röhl, C., Scharinger, R., Stamm, T., Strassnig, M., Wirthumer-Hoche, C., & Pleiner-Duxneuner, J. (2022). Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus. *JMIR Medical Informatics*, 10(6), e34204.

<https://doi.org/10.2196/34204>

35. Lentz, T. A., Curtis, L. H., Rockhold, F. W., Martin, D., Andersson, T. L. G., Arias, C., Berlin, J. A., Binns, C., Cook, A., Cziraky, M., Dent, R., Desai, M., Emmett, A., Esserman, D., George, J., Hantel, S., Heagerty, P., Hernandez, A. F., Hucko, T., ... Ellenberg, S. S. (2020). Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. *Therapeutic Innovation & Regulatory Science*, 54(6), 1477–1488. <https://doi.org/10.1007/s43441-020-00175-7>

36. Levenson, M., He, W., Chen, L., Dharmarajan, S., Izem, R., Meng, Z., Pang, H., & Rockhold, F. (2022). Statistical Consideration for Fit-for-Use Real-World Data to Support Regulatory Decision Making in Drug Development. *Statistics in Biopharmaceutical Research*, 0(0), 1–8. <https://doi.org/10.1080/19466315.2022.2120533>

37. Li, X., Lo Re III, V., & Toh, S. (2022). Profiling real-world data sources for pharmacoepidemiologic research: A call for papers. *Pharmacoepidemiology and Drug Safety*, 31(9), 929–931. <https://doi.org/10.1002/pds.5481>

38. Ligang Luo, Pingyan Chen, Jianing Di, Jun Wang, & Chunquan Ou. (2021, April). *Guideline on Using Real-World Data to Generate Real-World Evidence (Trial Version)*. Center for Drug Evaluation, NMPA. <http://www.gdbiost.org/uploads/files/%E3%80%8AGuideline%20on%20Using%20Real-World%20Data%20to%20Generate%20Real-World%20Evidence%E3%80%8B-RWD%E8%AF%95%E8%A1%8C.pdf>

39. Luca Foschini, Bray Patrick-Lake, Anusha Narayan, & Mikki Nasch. (2022). *Next Generation Patient Engagment & Enriched Insights: Increasing Confidence in Person-Generated Health Data (PGHD) and its Impact on Clinical Decision Making*. evalidation. https://pages.evalidation.com/hubfs/Evalidation%20Next%20Generation%20Patient%20Engagement%20&%20Enriched%20Insights_May%202022.pdf

40. Lydia Wenxin Lin, Jeonghoon Ahn, Diana Beatriz S. Bayani, Kelvin Chan, Dechen Choiphel, Wandrudee Isaranuwatjai, Sarin KC, Brendon Kearney, Jing Lou, Ryota Nakamura, Fiona Pearce, Shankar Prinja, Raoh-Fang PWU, Asrul Akmal Shafie, Yot Teerawattananon, Sean Tunis, Hui-Min Wu, John Zalcborg, & Hwee-Lin Wee. (2020, November 1). *Use of Real-World Data and Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia*. REALISE Group. https://hiper.nus.edu.sg/wp-content/uploads/2021/03/REALISE-Full-guidance-post-feedback_20201211-version-1.1.pdf

41. Makhmutova, M. (Ed.). (2021). *Predicting changes in depression using person-generated*

health data.

42. Marc Berger, James Li, William Crown, & Kelly Zou. (2023). *ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making*. <https://doi.org/10.21203/rs.3.rs-3025202/v1>
43. Nirosha Mahendraratnam, Christina Silcox, Kerra Mercon, Adam Kroetsch, Morgan Romine, Nicholas Harisson, Adam Aten, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, September 26). *Determining Real-World Data's Fitness for Use and the Role of Reliability*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/determining-real-world-datas-fitness-use-and-role-reliability>
44. O'Leary, C. P., & Cavender, M. A. (2020). Emerging opportunities to harness real world data: An introduction to data sources, concepts, and applications. *Diabetes, Obesity and Metabolism*, 22(S3), 3–12. <https://doi.org/10.1111/dom.13948>
45. Orsini, L. S., Berger, M., Crown, W., Daniel, G., Eichler, H.-G., Goettsch, W., Graff, J., Guerino, J., Jonsson, P., Lederer, N. M., Monz, B., Mullins, C. D., Schneeweiss, S., Brunt, D. V., Wang, S. V., & Willke, R. J. (2020). Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative. *Value in Health*, 23(9), 1128–1136. <https://doi.org/10.1016/j.jval.2020.04.002>
46. Rachael L. DiSantostefano, Erica A Voss, & Clair Blacketer. (2020). *"Fake News" in the Rush to Inform on COVID-19: How Research Retraction Can Inform Best Practices for Real-World Data Quality and Reporting*. Janssen Research and Development. https://www.ohdsi.org/wp-content/uploads/2020/10/DiSantostefano-Abstract_COVID19-Retractions-Inform-RWD-Quality-and-Reporting-Standards_2020symposium.pdf
47. Raman, S. R., O'Brien, E. C., Hammill, B. G., Nelson, A. J., Fish, L. J., Curtis, L. H., & Marsolo, K. (2022). Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: Reported practices and recommendations. *Journal of the American Medical Informatics Association*, 29(5), 798–804. <https://doi.org/10.1093/jamia/ocac004>
48. *Regulatory considerations on artificial intelligence for health*. (2022, September). ITU Publications. https://www.itu.int/dms_pub/itu-t/opb/fg/T-FG-AI4H-2022-3-PDF-E.pdf
49. Reynolds, M. W., Bourke, A., & Dreyer, N. A. (2020). Considerations when evaluating real-world data quality in the context of fitness for purpose. *Pharmacoepidemiology and*

Drug Safety, 29(10), 1316–1318. <https://doi.org/10.1002/pds.5010>

50. Rivera, D. R., Henk, H. J., Garrett-Mayer, E., Christian, J. B., Belli, A. J., Bruinooge, S. S., Espirito, J. L., Sweetnam, C., Izano, M. A., Natanzon, Y., Robert, N. J., Walker, M. S., Cohen, A. B., Boyd, M., Enewold, L., Hansen, E., Honnold, R., Kushi, L., Mishra Kalyani, P. S., ... Allen, J. D. (2022). The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*, 111(1), 283–292. <https://doi.org/10.1002/cpt.2453>
51. Ru, B., Sillah, A., Desai, K., Chandwani, S., Yao, L., & Kothari, S. (2024). Real-World Data Quality Framework for Oncology Time to Treatment Discontinuation Use Case: Implementation and Evaluation Study. *JMIR Medical Informatics*, 12(1), e47744. <https://doi.org/10.2196/47744>
52. Ryan J. Shaw, Mina Boazak, Victoria Tiase, Gloria Porter, Jedrek Wosik, Sarah Bumatay, LeAnn Michaels, Julie Stone, Deborah Cohen, & Rowena Dolor. (2021, May). *Integrating Patient-Generated Digital Health Data into Electronic Health Records in Ambulatory Care Settings: An Environmental Scan*. Agency for healthcare Research and Quality. https://www.researchgate.net/profile/Gloria-Porter/publication/356105655_Environmental_Scan_Report_Integrating_Patient-Generated_Digital_Health_Data_into_Electronic_Health_Records_in_Ambulatory_Care_Settings_An_Environmental_Scan/links/618be95961f09877207a85e7/Environmental-Scan-Report-Integrating-Patient-Generated-Digital-Health-Data-into-Electronic-Health-Records-in-Ambulatory-Care-Settings-An-Environmental-Scan.pdf
53. Sengupta, S., Ntambwe, I., Tan, K., Liang, Q., Paulucci, D., Castellanos, E., Fiore, J., Lane, S., Micsinai Balan, M., Viraswami-Apanna, K., Sethuraman, V., Samant, M., & Tiwari, R. (2023). Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study. *Clinical Pharmacology & Therapeutics*, 113(4), 867–877. <https://doi.org/10.1002/cpt.2841>
54. Solà-Morales, O., Sigurðardóttir, K., Akehurst, R., Murphy, L. A., Mestre-Ferrandiz, J., Cunningham, D., & de Pouvourville, G. (2023). Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. *Value in Health*. <https://doi.org/10.1016/j.jval.2023.02.012>
55. Sudha R. Raman, Suzanne N. Landi, Jennifer L. Lund, & Michele Jonsson Funk. (2021). Approaches to mitigate bias in the design and analysis of pRCTs. In *Pragmatic Randomized Clinical Trials: Using Primary Data Collection and Electronic Health Records* (pp. 131–149).
56. Swaminathan, A. C., Snyder, L. D., Hong, H., Stevens, S. R., Long, A. S., Yanchenko, E.,

- Qiu, Y., Liu, R., Zhang, H., Fischer, A., Burns, L., Wruck, L. M., & Palmer, S. M. (2023). External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. *American Journal of Respiratory and Critical Care Medicine*, 208(5), 579–588. <https://doi.org/10.1164/rccm.202210-1947OC>
57. Tadrous, M., Aves, T., Fahim, C., Riad, J., Mittmann, N., Prieto-Alhambra, D., Rivera, D. R., Chan, K., Lix, L. M., Kent, S., Dawoud, D., Guertin, J. R., McDonald, J. T., Round, J., Klarenbach, S., Stanojevic, S., De Vera, M. A., Strumpf, E., Platt, R. W., ... Hayes, K. N. (2024). Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making. *Journal of Clinical Epidemiology*, 176, 111545. <https://doi.org/10.1016/j.jclinepi.2024.111545>
58. Thompson, D. (2021). Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? *Value in Health*, 24(1), 112–115. <https://doi.org/10.1016/j.jval.2020.09.015>
59. Wang, J., Chen, J., Zhao, J., Wu, Y., Xin, X., & Chen, P. (2024). Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>
60. Zou, K. H., & Berger, M. L. (2024). Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union. *Bioengineering*, 11(8), Article 8. <https://doi.org/10.3390/bioengineering11080784>
61. Zura, R., Irwin, D. E., Mack, C. D., Aldridge, M. L., & Mackowiak, J. I. (2021). Real-World Evidence: A Primer. *Journal of Orthopaedic Trauma*, 35, S1. <https://doi.org/10.1097/BOT.0000000000002037>

Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility

“The Credibility Paper” | Published November 2019

1. Dang LE, Gruber S, Lee H, et al. A Causal Roadmap for Generating High-Quality Real-World Evidence. Published online May 11, 2023. doi:10.48550/arXiv.2305.06850
2. Beyrer J, Abedtash H, Hornbuckle K, Murray JF. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. *Journal of Comparative Effectiveness Research*. 2022;11(7):499-511. doi:10.2217/ce-2022-0006
3. He W, Fang Y, Wang H, Chan I. Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*. 2023;15(1):57-68. doi:10.1080/19466315.2021.1927827
4. He W, Zhang Z, Dharmarajan S. Assessment of Fit-for-Use Real-World Data Sources and Applications. In: He W, Fang Y, Wang H, eds. *Real-World Evidence in Medical Product Development*. Springer International Publishing; 2023:45-61. doi:10.1007/978-3-031-26328-6_4
5. Marc Berger, James Li, William Crown, Kelly Zou. ATRAcTR (Authentic Transparent Relevant Accurate Track-Record): A Screening Tool to Assess the Potential for Real-World Data Sources to Support Creation of Credible Real-World Evidence for Regulatory Decision-Making. Published online June 7, 2023. doi:<https://doi.org/10.21203/rs.3.rs-3025202/v1>
6. Mack CD, Pavesio A, Kelly K, et al. Breaking Barriers: Studying Fracture Healing in the BONES Program. *Journal of Orthopaedic Trauma*. 2021;35:S22. doi:10.1097/BOT.0000000000002035
7. Yukari Uemura, Ryoto Ozaki, Tomohiro Shinozaki, Hiroshi Ohtsu. Comparative Effectiveness of Tocilizumab vs Standard Care in Patients with severe COVID-19–related Pneumonia: A retrospective cohort study utilizing registry data as a synthetic control. doi:10.21203/rs.3.rs-2866088/v1
8. Lauren Elizabeth Eyler Dang. *Development and Application of the Experiment-Selector Cross-Validated Targeted Maximum Likelihood Estimator*. University of California, Berkeley; 2023. Accessed March 6, 2024. <https://www.proquest.com/docview/2869145998?pq-origsite=gscholar&fromopenview=true&sourcetype=Dissertations%20&%20Theses>

9. O'Donnell JC, Le TK, Dobrin R, et al. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. *Future Oncology*. 2021;17(3):333-347. doi:10.2217/fon-2020-0591
10. Carrigan G, Bradbury BD, Brookhart MA, et al. External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Challenges. *Curr Epidemiol Rep*. 2022;9(4):326-337. doi:10.1007/s40471-022-00305-9
11. Shau WY, Setia S, Shinde S, Santoso H, Furtner D. Generating fit-for-purpose real-world evidence in Asia: How far are we from closing the gaps? *Perspect Clin Res*. 2023;14(3):108-113. doi:10.4103/picr.picr_193_22
12. Dreyer NA, Hall M, Christian JB. Modernizing Regulatory Evidence with Trials and Real-World Studies. *Ther Innov Regul Sci*. 2020;54(5):1112-1115. doi:10.1007/s43441-020-00131-5
13. Fisher VA, Comment LA. Multi-state survival models with treatment effects and biomarkers: Simulations for study design assessment. *Cancer Epidemiology*. 2022;81:102272. doi:10.1016/j.canep.2022.102272
14. Jaks A, Wu J, Jónsson P, Eichler HG, Vittoe S, Gatto NM. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. *Journal of Comparative Effectiveness Research*. 2021;10(9):711-731. doi:10.2217/cer-2020-0228
15. Acha V, Barefoot B, Juarez Garcia A, et al. Principles for Good Practice in the Conduct of Non-interventional Studies: The View of Industry Researchers. *Ther Innov Regul Sci*. Published online July 17, 2023. doi:10.1007/s43441-023-00544-y
16. Franklin JM, Liaw KL, Iyasu S, Critchlow CW, Dreyer NA. Real-world evidence to support regulatory decision making: New or expanded medical product indications. *Pharmacoepidemiology and Drug Safety*. 2021;30(6):685-693. doi:10.1002/pds.5222
17. Sheffield KM, Dreyer NA, Murray JF, Faries DE, Klopchin MN. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions. *Journal of Comparative Effectiveness Research*. 2020;9(15):1043-1050. doi:10.2217/cer-2020-0161
18. Murphy LA, Akehurst R, Solà-Morales O, et al. Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers. *Value in Health*. 2023;26(4, Supplement):20-31. doi:10.1016/j.jval.2023.01.007

19. Nirosha Mahendraratnam, Joy Eckert, Kerra Mercon, et al. Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility. Published online November 25, 2019. <https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world>
20. Wherry K, Stromberg K, Hinnenthal JA, Wallenfelsz LA, El-Chami MF, Bockstedt L. Using Medicare Claims to Identify Acute Clinical Events Following Implantation of Leadless Pacemakers. *Pragmat Obs Res.* 2020;11:19-26. doi:10.2147/POR.S240913
21. Broek RWM van den, Matheis RJ, Bright JL, Hartog TE, Perfetto EM. Value-based evidence across health care sectors: a push for transparent real-world studies, data, and evidence dissemination. *Health Economics, Policy and Law.* 2022;17(4):416-427. doi:10.1017/S1744133122000056

Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness

“The Totality of Evidence Paper” | Published December 2019

1. *A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2- Metastatic Breast Cancer.* (n.d.). Jadpro. Retrieved November 27, 2024, from <https://jadpro.com/online-first/2024/a-real-world-evidence-primer-for-advanced-practice-providers-integrating-p-reality-x-into-shared-decision-making-for-people-with-hrplusher2-metastatic-breast-cancer/>
2. Beena Bhuiyan Khan. (2021, August 11). *View Public Comments for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (CAG-00460N).*
3. Boikos, C., Imran, M., De Lusignan, S., Ortiz, J. R., Patriarca, P. A., & Mansi, J. A. (2022). Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines, 10*(5), Article 5. <https://doi.org/10.3390/vaccines10050727>
4. Boikos, C., McGovern, I., Molrine, D., Ortiz, J. R., Puig-Barberà, J., & Haag, M. (2022). Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. *Vaccines, 10*(6), Article 6. <https://doi.org/10.3390/vaccines10060896>
5. Boikos, C., McGovern, I., Ortiz, J. R., Puig-Barberà, J., Versage, E., & Haag, M. (2022). Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States. *Vaccines, 10*(9), Article 9. <https://doi.org/10.3390/vaccines10091456>
6. Bourla, A. B., & Herrmann, K. (2021). Real-World Data as an Evidence Source in Nuclear Medicine. *Journal of Nuclear Medicine, 62*(2), 156–157. <https://doi.org/10.2967/jnumed.120.258665>
7. Burns, L., Le Roux, N., Kalesnik-Orszulak, R., Christian, J., Dudinak, J., Rockhold, F., Khozin, S., & O’Donnell, J. (2023). Real-world evidence for regulatory decision-making: Updated guidance from around the world. *Frontiers in Medicine, 10*, 1236462. <https://doi.org/10.3389/fmed.2023.1236462>
8. *Contemporary Applications of Real-World Evidence in Regulatory Decision Making: A Case Series Review – Medical Affairs Professional Society.* (n.d.). Retrieved December 8, 2022, from <https://medicalaffairs.org/real-world-evidence-regulatory-decision-making/>
9. Dreyer, N. A., Hall, M., & Christian, J. B. (2020). Modernizing Regulatory Evidence with Trials and Real-World Studies. *Therapeutic Innovation & Regulatory Science, 54*(5), 1112–

1115. <https://doi.org/10.1007/s43441-020-00131-5>

10. Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2022). Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019. *Clinical Pharmacology & Therapeutics*, 111(1), 310–320. <https://doi.org/10.1002/cpt.2462>
11. Evgenia Alekseevna. (2022). *PHARMACOEPIDEMIOLOGICAL AND CLINICAL AND ECONOMIC EVALUATION OF PSORIASIS THERAPY IN REAL PRACTICE IN THE RUSSIAN FEDERATION* [Federal State Autonomous Educational Institution higher education “Peoples’ Friendship University of Russia”]. https://www.volgmed.ru/uploads/dsovet/thesis/2-993-novoderezhkina_evgeniya_alekseevna.pdf
12. Fleurence, R. L., Kent, S., Adamson, B., Tcheng, J., Balicer, R., Ross, J. S., Haynes, K., Muller, P., Campbell, J., Bouée-Benhamiche, E., García Martí, S., & Ramsey, S. (2024). Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force. *Value in Health*, 27(6), 692–701. <https://doi.org/10.1016/j.jval.2024.01.019>
13. Girman, C. J., Ritchey, M. E., McNeill, A. M., Sundell, K. A., & Meyer, R. J. (2021). Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims. *Therapeutic Innovation & Regulatory Science*, 55(3), 561–567. <https://doi.org/10.1007/s43441-020-00252-x>
14. James A Rogers, Hugo Maas, & Alejandro Perez. (2022, October). *Analysis Planning and Interpretation Using Causal Directed Acyclic Graphs: A Case Study in Oncology*. <https://metrumrg.com/wp-content/uploads/2022/10/dags-acop2022-poster.pdf>
15. Kugener, V. F., Freedland, E. S., Maynard, K. I., Aimer, O., Webster, P. S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. *Drug Safety*, 44(8), 843–852. <https://doi.org/10.1007/s40264-021-01078-8>
16. Lynch, H. F., & Bateman-House, A. (2020). Facilitating Both Evidence and Access: Improving FDA’s Accelerated Approval and Expanded Access Pathways. *Journal of Law, Medicine & Ethics*, 48(2), 365–372. <https://doi.org/10.1177/1073110520935352>
17. Mack, C. D., Pavesio, A., Kelly, K., Irwin, D. E., Maislin, G., Jones, J., Wester, T., & Zura, R. (2021). Breaking Barriers: Studying Fracture Healing in the BONES Program. *Journal of Orthopaedic Trauma*, 35, S22. <https://doi.org/10.1097/BOT.0000000000002035>
18. Mahendraratnam, N., Mercon, K., Gill, M., Benzing, L., & McClellan, M. B. (2022).

- Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness. *Clinical Pharmacology & Therapeutics*, 111(1), 150–154. <https://doi.org/10.1002/cpt.2272>
19. McDermott, O., & Kearney, B. (n.d.). The value of using real-world evidence as a source of clinical evidence in the European medical device regulations: A mixed methods study. *Expert Review of Medical Devices*, 1–15. <https://doi.org/10.1080/17434440.2023.2291454>
 20. Nirosha Mahendraratnam, Kerra Mercon, Joy Eckert, Morgan Romine, Adam Kroetsch, Katherine Frank, Rachel Sherman, Gregory Daniel, & Mark McClellan. (2019, December 19). *Adding Real-World Evidence to a Totality of Evidence Approach for Evaluating Marketed Product Effectiveness*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product>
 21. Novoderezhkina, E. A., & Zyryanov, S. K. (2022). The role of real world data and real world evidence in health technology assessment. *FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology*, 15(3), Article 3. <https://doi.org/10.17749/2070-4909/farmakoeconomika.2022.120>
 22. Novoderezhkina, E. A., Алексеевна, Н. Е., Zyryanov, S. K., & Кенсаринович, З. С. (2021). THE ROLE OF REAL CLINICAL PRACTICE DATA IN MODERN HEALTHCARE. *Farmaciya (Pharmacy)*, 70(3), Article 3. <https://doi.org/10.29296/25419218-2021-03-01>
 23. Reed, S. D., & McLeod, L. (2020). Moving Beyond the Tip of the Iceberg to Incorporate Patients' Perspectives and Outcomes in the Medical Device Regulatory Process. *Value in Health*, 23(3), 298–299. <https://doi.org/10.1016/j.jval.2020.01.008>
 24. Reynolds, M. W., Bourke, A., & Dreyer, N. A. (2020). Considerations when evaluating real-world data quality in the context of fitness for purpose. *Pharmacoepidemiology and Drug Safety*, 29(10), 1316–1318. <https://doi.org/10.1002/pds.5010>
 25. Sarri, G., Patorno, E., Yuan, H., Guo, J. (Jeff), Bennett, D., Wen, X., Zullo, A. R., Largent, J., Panaccio, M., Gokhale, M., Moga, D. C., Ali, M. S., & Debray, T. P. A. (2022). Framework for the synthesis of non-randomised studies and randomised controlled trials: A guidance on conducting a systematic review and meta-analysis for healthcare decision making. *BMJ Evidence-Based Medicine*, 27(2), 109–119. <https://doi.org/10.1136/bmjebm-2020-111493>
 26. Wang, J., Chen, J., Zhao, J., Wu, Y., Xin, X., & Chen, P. (2024). Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*.

<https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>

27. Zou, K. H., Li, J. Z., Imperato, J., Potkar, C. N., Sethi, N., Edwards, J., & Ray, A. (2020). Harnessing Real-World Data for Regulatory Use and Applying Innovative Applications. *Journal of Multidisciplinary Healthcare*, 13, 671–679. <https://doi.org/10.2147/JMDH.S262776>
28. НОВОДЕРЕЖКИНА Е.А. & ЗЫРЯНОВ С.К. (2020). Роль данных реальной клинической практики в современном здравоохранении. 5–10. <https://doi.org/10.29296/25419218-2021-03-01>

A Roadmap for Developing Study Endpoints in Real-World Settings

“The RWE Endpoints Paper” | Published August 2020

1. Kerra Mercon, Nirosha Mahendraratnam, Joy Eckert, et al. A Roadmap for Developing Study Endpoints in Real-World Settings. Published online August 28, 2020. <https://healthpolicy.duke.edu/publications/roadmap-developing-study-endpoints-real-world-settings>
2. Stern AD, Brönneke J, Debatin JF, et al. Advancing digital health applications: priorities for innovation in real-world evidence generation. *The Lancet Digital Health*. 2022;4(3):e200-e206. doi:10.1016/S2589-7500(21)00292-2
3. He W, Fang Y, Wang H, Chan I. Applying Quantitative Approaches in the Use of RWE in Clinical Development and Life-Cycle Management. *Statistics in Biopharmaceutical Research*. 2021;0(0):1-12. doi:10.1080/19466315.2021.1927827
4. Sola-Morales O, Curtis LH, Heidt J, et al. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory & HTA Decisions. *Clinical Pharmacology & Therapeutics*. n/a(n/a). doi:10.1002/cpt.2914
5. Wang J, Chen J, Zhao J, Wu Y, Xin X, Chen P. Establishment of RWS guidance reflecting contributions of China to regulatory science. *Journal of Biopharmaceutical Statistics*. Published online March 17, 2024. Accessed June 4, 2024. <https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2330208>
6. Chen J, Scharfstein D, Wang H, et al. Estimands in Real-World Evidence Studies. *Statistics in Biopharmaceutical Research*.:1-13. doi:10.1080/19466315.2023.2259829
7. Jaksa A, Bloudek L, Carlson JJ, et al. Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot. *International Journal of Technology Assessment in Health Care*. 2022;38(1):e32. doi:10.1017/S0266462322000162
8. Jaksa A, Mahendraratnam N. Learning from the past to advance tomorrow's real-world evidence: what demonstration projects have to teach us. *Journal of Comparative Effectiveness Research*. 2021;10(16):1169-1173. doi:10.2217/cer-2021-0166
9. Burns L, Roux NL, Kalesnik-Orszulak R, et al. Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World. *Clinical Therapeutics*. 2022;44(3):420-437. doi:10.1016/j.clinthera.2022.01.012
10. Alipour-Haris G, Liu X, Acha V, Winterstein AG, Burcu M. Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases. *Clinical and Translational Science*. 2024;17(8):e13903. doi:10.1111/cts.13903

11. Beyrer J. *Regulatory Acceptable Real-World Effectiveness Endpoints: How Clarity Can Best Be Achieved in the United States*. Ph.D. Indiana University - Purdue University Indianapolis; 2023. Accessed March 6, 2024.
<https://www.proquest.com/docview/2908925189/abstract/2FBBFAB790144CA3PQ/1>
12. Cottu P, Ramsey SD, Solà-Morales O, Spears PA, Taylor L. The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making. *The Breast*. 2022;61:118-122. doi:10.1016/j.breast.2021.12.015
13. Rivera DR, Henk HJ, Garrett-Mayer E, et al. The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies. *Clinical Pharmacology & Therapeutics*. 2022;111(1):283-292. doi:10.1002/cpt.2453
14. Khambholja K, Gehani M. Use of Structured Template and Reporting Tool for Real-World Evidence for Critical Appraisal of the Quality of Reporting of Real-World Evidence Studies: A Systematic Review. *Value in Health*. 2023;26(3):427-434. doi:10.1016/j.jval.2022.09.003

Point-of-Care Clinical Trials: Integrating Research and Care Delivery

“The POC Paper” | Published May 2022

1. Bahls, Christine. “‘Record’ Gains in Bringing Research Closer to the Patient.” *Applied Clinical Trials* 31, no. 9 (September 2022): 19–22.
2. Burns, Leah, Nadege Le Roux, Robert Kalesnik-Orszulak, Jennifer Christian, Jennifer Dudinak, Frank Rockhold, Sean Khozin, and John O’Donnell. “Real-World Evidence for Regulatory Decision-Making: Updated Guidance from around the World.” *Frontiers in Medicine* 10 (October 30, 2023): 1236462. <https://doi.org/10.3389/fmed.2023.1236462>.
3. Caleigh Propes, Sarah Sheehan, and Rachele Hendricks-Sturup. “Point-of-Care Clinical Trials: Integrating Research and Care Delivery.” Duke-Margolis Center for Health Policy, May 11, 2022. <https://healthpolicy.duke.edu/publications/point-care-clinical-trials-integrating-research-and-care-delivery>.
4. Dombeck, Carrie, Teresa Swezey, Lindsay Kehoe, Kraig Kinchen, Matthew Roe, Mark Stewart, and Amy Corneli. “Embedding Clinical Trial Elements into Clinical Practice: Experiences from Trial Designers and Implementers.” *Journal of Clinical and Translational Science* 8, no. 1 (January 2024): 202. <https://doi.org/10.1017/cts.2024.647>.
5. Hau, Cynthia, Patricia A. Woods, Amanda S. Guski, Srihari I. Raju, Liang Zhu, Patrick R. Alba, William C. Cushman, et al. “Strategies for Secondary Use of Real-World Clinical and Administrative Data for Outcome Ascertainment in Pragmatic Clinical Trials.” *Journal of Biomedical Informatics* 150 (February 1, 2024): 104587. <https://doi.org/10.1016/j.jbi.2024.104587>.
6. Hendricks-Sturup, Rachele, and Dixil Francis. “Evidence on Real-World Data and Real-World Evidence As a Driver for Precision Medicine Implementation in Pharmacy Practice.” In *Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy*, 1–12. Cham: Springer International Publishing, 2020. https://doi.org/10.1007/978-3-030-50247-8_93-1.
7. Leatherman, Sarah M., and Areef Ishani. “Point of Care Clinical Trials in Nephrology.” *Journal of the American Society of Nephrology*, February 7, 2024, 10.1681/ASN.0000000000000340. <https://doi.org/10.1681/ASN.0000000000000340>.
8. Peters, Anthony E., W. Schuyler Jones, Brian Anderson, Carolyn T. Bramante, Uli Broedl, Christoph P. Hornik, Lindsay Kehoe, et al. “Framework of the Strengths and Challenges of Clinically Integrated Trials: An Expert Panel Report.” *American Heart Journal* 275 (September 1, 2024): 62–73. <https://doi.org/10.1016/j.ahj.2024.05.009>.
9. Ridgeway, Jennifer L., Wendy J. S. Sundt, Tami S. Krpata, Amy Glasgow, Olivia A. Smith, Michelle A. Lampman, Jamie L. Smith-Stellflug, et al. “Evaluating Adoption and Reach in a Pragmatic Randomized Trial of Community Paramedicine for Intermediate Acuity

Patient Care." *Journal of Clinical and Translational Science* 8, no. 1 (January 2024): e199.
<https://doi.org/10.1017/cts.2024.646>.

Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Evidence Ecosystem

“The SEO Paper” | Published July 2022

1. Burns, L., Le Roux, N., Kalesnik-Orszulak, R., Christian, J., Dudinak, J., Rockhold, F., Khozin, S., & O'Donnell, J. (2023). Real-world evidence for regulatory decision-making: Updated guidance from around the world. *Frontiers in Medicine*, *10*, 1236462. <https://doi.org/10.3389/fmed.2023.1236462>
2. Dunger-Baldauf, C., Hemmings, R., Bretz, F., Jones, B., Schiel, A., & Holmes, C. (2023). Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs. *Clinical Pharmacology & Therapeutics*, *113*(5), 1132–1138. <https://doi.org/10.1002/cpt.2869>
3. Oberprieler, N. G., Pladevall-Vila, M., Johannes, C., Layton, J. B., Golozar, A., Lavallee, M., Liu, F., Kubin, M., & Vizcaya, D. (2024). FOUNTAIN: A modular research platform for integrated real-world evidence generation. *BMC Medical Research Methodology*, *24*(1), 224. <https://doi.org/10.1186/s12874-024-02344-w>
4. Rebecca Ray, Trevan Locke, & Rachele Hendricks-Sturup. (2022, July 20). *Aligning Shared Evidentiary Needs Among Payers and Regulators for a Real-World Data Ecosystem*. Duke-Margolis Center for Health Policy. <https://healthpolicy.duke.edu/publications/aligning-shared-evidentiary-needs-among-payers-and-regulators-real-world-data>

Improving Patient Subgroup Representation with Real-World Data

“The Patients Subgroups Paper” | Published September 2023

1. Gressler LE, Marinac-Dabic D, Resnic FS, et al. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks. *Ther Innov Regul Sci*. Published online July 25, 2024. doi:10.1007/s43441-024-00680-z
2. Schoonenboom J. Design Patterns in Mixed Methods Research: Embedding Mixed Methods Matched Comparisons Sampling in Previous Design Decisions. *Journal of Mixed Methods Research*. 2024;18(3):383-392. doi:10.1177/15586898241257284

Lessons from Learning Health Care Systems and Recommendations for Successful Implementation

“The LHS Paper” | Published October 2023

1. D’Ambrosio M, Locke T, Hendricks-Sturup R. Addressing Climate Change-Induced Tick-borne Lyme Disease Patterns Through Data-Driven ‘One Health’ Policy. *Journal of Public Health Management and Practice*. 2024;30(4):E157. doi:10.1097/PHH.0000000000001975

Real-World Evidence to Support Causal Inference: Methodological Considerations for Non-Interventional Studies

“The Causal Inference Paper” | Published June 2024

1. Rippin, G., & Sanz, H. (2024). External comparator studies and the joint application of the estimand and target trial emulation frameworks. *Frontiers in Drug Safety and Regulation*, 4. <https://doi.org/10.3389/fdsfr.2024.1409102>